

CURRICULUM VITAE

DR. PHILIP G. TIBBO

Professor
Dr. Paul Janssen Chair in Psychotic Disorders,
Department of Psychiatry, Dalhousie University,
Halifax, NS

February 21, 2017

NAME: Philip George TIBBO
Professor
Dr. Paul Janssen Chair in Psychotic Disorders

ADDRESS: Department of Psychiatry
Dalhousie University
Rm 3030-3rd Flr. Abbie Lane Bldg
5909 Veterans' Memorial Lane
Halifax, Nova Scotia
B3H 2E2

Tel: 902-473-1678
Fax: 902-425-9699
Email: phil.tibbo@nshealth.ca

DATE OF BIRTH: August 12, 1965

CITIZENSHIP: Canadian

EDUCATION AND QUALIFICATIONS

<u>Dates</u>	<u>Institution</u>	<u>Qualification</u>	<u>Year</u>
1982-86	Mount Allison University, NB	B.Sc. Honours	1986
1987-91	Memorial University of Newfoundland	B.Med.Sc.	1989
	Memorial University of Newfoundland	MD	1991
1991-92	Royal Alexandra Hospital, AB	Internship	1992
1993-97	University of Alberta, Psychiatry	FRCPC	1997
1997-2000	Clinical Research Fellow University of Alberta Psychiatry	AHFMR	2000

MEDICAL POSTS

<u>Date</u>	<u>Position</u>
1987-1991	Medical Student, Memorial University of Newfoundland, St. John's, NL, Canada
1991-1992	Rotating Intern, Royal Alexandra Hospital, Edmonton, AB, Canada
1992-1993	General Practitioner-Psychiatrist, Nova Scotia Psychiatric Hospital, Dartmouth, NS, Canada
1993-1997	Resident in Psychiatry, Department of Psychiatry, University of Alberta, Edmonton, AB, Canada
1995-1997	Co-Editor, <i>International Abstracts in Psychiatry</i> , Doer Press, Montreal, Quebec, Canada

1995-1997	Chief Resident, Residency Training Program, Department of Psychiatry, University of Alberta
1997-2000	Associate Director, Postgraduate Training Program in Psychiatry, University of Alberta, Edmonton, AB
1997-2000	Clinical Research Fellow, Alberta Heritage Foundation for Medical Research
1997-2007	Associate Director, Psychopharmacology Research Unit, University of Alberta
2000-2004	Director, Postgraduate Training Program in Psychiatry, University of Alberta
2000-2005	Assistant Professor, Department of Psychiatry, University of Alberta, Edmonton, AB
2001-2004	Clinical Investigator, Alberta Heritage Foundation for Medical Research, Univ. of Alberta
2001-present	Co-Director, Bebensee Schizophrenia Research Unit, Department of Psychiatry, University of Alberta, Edmonton, AB
2005-2008	Clinical Investigator, Alberta Heritage Foundation for Medical Research
2005-2008	Associate Professor, Department of Psychiatry, University of Alberta, Edmonton, AB
2006-2008	Clinical Director – Edmonton Early Psychosis Intervention Clinic (EEPIC), Edmonton
2008-present	Adjunct Professor, Department of Psychiatry, University of Alberta, Edmonton, AB
2008-present	Professor, Department of Psychiatry, Dalhousie University, Halifax, NS
2008-present	Dr. Paul Janssen Chair in Psychotic Disorders, Department of Psychiatry, Dalhousie University, Halifax, NS
2008-present	Co-Director – Nova Scotia Psychosis Research Unit (NSPRU), Halifax, NS
2008-present	Medical Advisor, Schizophrenia Society of Nova Scotia Board of Directors
2009-present	Director, Nova Scotia Early Psychosis Program (NSEPP) Halifax, NS
2009-present	Adjunct Professor, Department of Psychology (Dalhousie), Halifax, NS
2010-present	Consulting Medical Staff, Department of Psychiatry, IWK Children’s Health Centre, Halifax, NS.
2010-present	Member, Brain Repair Centre, QEII HSC/Dalhousie University, Halifax, NS

HONORS AND AWARDS

1982-83/1983-84	Leonard Foundation Scholarship - funded by Permanent Trust Company for academic and extracurricular activities, Mount Allison University
1984, 1985, 1986	Dean’s Honor Role, Mount Allison University
1985	Bell Junior Research Fellow - awarded for research in biology relating to honors thesis, Mount Allison University
1986	Ruggles-Gates Research Award - awarded by Mount Allison University Biology Department for honors thesis research
1986	Natural Sciences & Engineering Research Council of Canada (NSERC) - summer research award in Psychology to study animal models of Alzheimer’s disease, Mount Allison University
1986	Mount Allison Gold ‘A’ Award - awarded to a graduating student who demonstrated outstanding contribution to student life

- 1987-88/1988-89 Goodridge Scholarship - awarded to Mount Allison University graduates who are attending medical school; award based on academics and extracurricular activities
- 1988 John M. and Elsa S. Morgan Scholarship - awarded by Memorial University of Newfoundland Medical School for academics in first-year medicine
- 1991 Dr. Frank O'Dea Scholarship in Medicine - awarded to graduating student outstanding in the field of Obstetrics and Gynecology
- 1995 Annual Postgraduate Medical Publication Prize, University of Alberta - "Striatal Dopamine D2 Receptor Binding with ¹²³I-Epidepride in Schizophrenic Patients and Controls: A SPECT Study"
- 1995 & 1996 Janssen Schizophrenia Research Fellow - sixteen Canadian psychiatry residents with interested in schizophrenia research chosen to attend the American Psychiatric Association Annual Meeting to audit new research in schizophrenia. A partnership program with Janssen Pharmaceuticals, the Canadian Alliance for Research in Schizophrenia (CAROS), and COPE
- 1995 R.O. Jones Award - awarded for best research paper by a member-in-training at the 45th Canadian Psychiatric Association Annual Meeting (CPA), Victoria, British Columbia
- 1996 & 1997 Chairman's Research Prize - awarded by the Department of Psychiatry, University of Alberta, Edmonton
- 1997 Laughlin Fellow - awarded by the American College of Psychiatrists
- 1997 President's Prize - awarded for best scientific paper presented by a resident at the Alberta Psychiatric Association Annual Meeting, Banff, Alberta. "Shape and Size Morphology of the Corpus Callosum in Male Schizophrenics"
- 1997 R.H. Mewburn Memorial Prize in Clinical and Liaison Psychiatry - awarded by the Department of Psychiatry, University of Alberta, Edmonton
- 1997 Canadian Association of Professors and Psychiatry (CAPP) - Research Award
- 1997-2000 Alberta Heritage Foundation for Medical Research (AHFMR) Clinical Research Fellowship - Supervisors: Dr. P. Allen, Chair, Biomedical Engineering, University of Alberta and Dr. P. Nopoulos Assistant Professor, University of Iowa
- 1998-2001 NARSAD Young Investigator Award
- 1999 Lilly Fellowship Award - awarded by the Society of Biological Psychiatry
- 1999 Fellow - XI World Congress of Psychiatry, WPA in Hamburg, Germany
- 2000 Best Poster Award - awarded at the Canadian Psychiatric Association (CPA) Annual Meeting (Victoria, BC) "Edmonton High Risk Project"
- 2001-2004 Alberta Heritage Foundation for Medical Research (AHFMR) Clinical Investigator Award
- 2001-2003 NARSAD Young Investigator Award
- 2002 Certificate of Appreciation for Teaching - awarded by the Faculty of Medicine and Dentistry, University of Alberta
- 2002 Poster Prize Award - 3rd place awarded at the Association for Academic Psychiatry (AAP) Annual Meeting (Toronto, ON) "Perception of Intimidation in the Psychiatry Education Environment in Edmonton, Alberta"
- 2002-2003 Association for Academic Psychiatry (AAP)/GlaxoSmithKline Junior Faculty Development Award - in recognition of excellence in psychiatric education and great promise for continued development as an educator

2003-2004	Certificate of Appreciation for Teaching - awarded by the Faculty of Medicine and Dentistry, University of Alberta
2004	Spotlight on Achievement in Research - awarded by the Faculty of Medicine and Dentistry, University of Alberta
2004-2005	Certificate of Appreciation for Teaching - awarded by the Faculty of Medicine and Dentistry, University of Alberta
2005	REACH Innovation Award (Recognition of Excellence and Achievement in Capital Health) - Edmonton Early Psychosis Intervention Clinic (EEPIC)
2005-2008	Alberta Heritage Foundation for Medical Research (AHFMR) Clinical Investigator Award
2010	Best Poster Award, Dalhousie, Department of Psychiatry Academic Day – “Help seeking pathways in first-episode psychosis”.
2010	Best Poster Award, 8 th Atlantic Canada Psychosis Conference - “Help seeking pathways in first-episode psychosis”.
2012	Mental Health Commission of Canada 5 th Anniversary National Mental Health Awards – Research. “Understanding the link between cannabis and psychosis: An awareness strategy for youth” [research lead on project run in collaboration with the Schizophrenia Society of Canada]
2013	Fellow of the Canadian Psychiatric Association awarded by Canadian Psychiatric Association
2015	Michael Smith Award; awarded by the Schizophrenia Society of Canada for research and leadership in schizophrenia

COMMITTEE POSITIONS (Selective)

Local:

1998-2008	Member, Edmonton Schizophrenia Conference Planning Committee
2006-2008	Chair, Edmonton Schizophrenia Conference Planning Committee
1998-2003	Member, Update on the Management of Psychosis Planning Committee
1998-2005	Member, Graduate Program Committee, Department of Psychiatry, University of Alberta
2000-2004	Chair, Postgraduate Medical Education Committee in Psychiatry (PGME), Department of Psychiatry, University of Alberta
2000-2004	Member, Postgraduate Medical Education Internal Reviews Committee, Faculty of Medicine & Dentistry, University of Alberta
2005	Member, Search & Selection Committee, GFT in Forensic Psychiatry, Edmonton, AB
2006	Member, Search & Selection Committee, Division Head of Forensic Psychiatry, Edmonton, AB
2006	Member, Search & Selection Committee, NMR Research Facility Director, Edmonton, AB
2009-present	Member, Research Committee, Dept. of Psychiatry, Dalhousie University
2011-2012	Member, Search & Selection Committee, Head of Pharmacology, Dalhousie University
2014-present	Co-Chair, Capital Health Addictions and Mental Health Program (CHAMHP) - Quality Council

2014-present	Co-Chair, Capital Health Addictions and Mental Health Program (CHAMHP) – Pathways Redesign Project for Psychosis
Provincial:	
2004-2007	Co-Chair, Scientific Committee for the Alberta Psychiatric Association (APA) Annual Meeting
2004-2007	Member, Alberta Heritage Foundation for Medical Research (AHFMR) Health Trainee Advisory Committee
2011-2013	Steering Committee, NRC-IBD (Atlantic), Halifax, NS
National:	
2002-2003	Secretary/Treasurer, Coordinators of Postgraduate Education in Psychiatry (COPE), Canada
2003-2004	Co-Chair, Coordinators of Postgraduate Education in Psychiatry (COPE), Canada
2003-2013	Member, OSCE Test Committee, Medical Council of Canada
2004-2008	Vice-Chair, Royal College of Physicians and Surgeons of Canada (RCPSC) Examination Committee and Board for Psychiatry
2005	Consultant, Annual Conference Program Committee, 55 th Canadian Psychiatric Association Annual Conference
2005-present	Member, Editorial Board, <i>Academic Psychiatry</i>
2005-present	Member, Editorial Board, <i>Canadian Journal of Psychiatry</i>
2008-2010	Chair, RCPSC Examination Committee and Board (English) for Psychiatry
2011-present	Board member, Schizophrenia Society of Canada
2012-present	Chair, Schizophrenia Society of Canada Foundation
2012-present	Canadian Psychiatry Association Research Committee, Dalhousie University Representative
2013-present	Member, Institute for Psychosocial Research in Mental Illness Development Team (initiated by the Schizophrenia Society of Ontario)
2013-2015	Member, Psychiatry Practice Eligibility Route B (PER) Test Committee, RCPSC
2013-present	Member, Canadian College of Health Leaders – Awards Committee for “Award of Excellence in Mental Health Quality Improvement” 2013-2014
2014-present	Board Member – Canadian Consortium for Early Intervention in Psychosis
2014-present	Co-Chair, Canadian Psychiatric Association Junior Research Colloquium
2016-present	Member, Award of Excellence in Mental Health and Quality Improvement Selection Committee, Canadian College of Health Leaders
2016-present	President, Canadian Consortium for Early Intervention in Psychosis

PROFESSIONAL MEMBERSHIPS

1987-1991	Professional Association of Interns and Residents of Newfoundland
1993-1997	Professional Association of Interns and Residents of Alberta
1991-1993	Nova Scotia Medical Association
1993-1998	American Psychiatric Association
1991-2013	Alberta Medical Association

1991-2013	College of Physicians and Surgeons of Alberta
1993- 2013	Alberta Psychiatric Association
1991-present	Canadian Medical Association
1993-present	Canadian Psychiatric Association
1998-present	International Society for Neuroimaging in Psychiatry (ISNIP)
1997-present	Royal College of Physicians and Surgeons of Canada
1998-present	Canadian College of Neuropsychopharmacology (CCNP)
1999-present	Society of Biological Psychiatry
2008-present	College of Physicians and Surgeons of Nova Scotia
2011-present	Schizophrenia International Research Society (SIRS)
2013-present	Canadian Consortium for Early Intervention in Psychosis

TEACHING (classroom)

1996	Pharmacy 489 - Advanced Therapeutics (Psychotropic Section), invited critic of group case presentations, University of Alberta
1996 & 1997	Phase II Medical Students, Small Group Teaching of Psychiatry, University of Alberta
1997	Movement Disorder Workshop, Dr. Richard Williams, University of Alberta, September 8 th
1997-2000	Psychopharmacology section of the LMCC Review Course, University of Alberta Medical School
2002-2007	Psychiatry 511 (Schizophrenia and Psychosis), University of Alberta
2003-2005	Psychiatry PGY-V Seminar: (Transition to Practice), University of Alberta
2005	Psych 688 - MRS, fMRI and DTI Schizophrenia Research at the University of Alberta
1997-2008	Psychiatry Resident PGY-II Seminars: 1) Schizophrenia, Paranoid and other Psychosis; 2) Neuroimaging; 3) First Episode Psychosis; 4) Biological Theories of Schizophrenia; University of Alberta
2012-present	Psychiatry Resident Journal Club (Dalhousie University)

TEACHING (non-classroom)

*Postdoctoral Fellows, Students and Residents for Whom I was Primary Supervisor or *Co-supervisor, University of Alberta, Edmonton, Alberta/Dalhousie University, Halifax, NS*

- (A) Professional Research Assistants:
- (i) Dr. Sheila Asghar, July 1997 - June 1998 (Projects related to the Psychopharmacology Research Unit)
 - (ii) Ms. Agitha Valiakalayil, July 1998 - September 1999 (Adolescents at risk for schizophrenia)
 - (iii) *Ms. Lori Anne Paulson, May 1999 - August 2001 (¹H-MRS in schizophrenia)
 - (iv) Mr. Ian Harding, May - August 2005 (procedural learning skills in schizophrenia via fMRI)
 - (v) Ms. Agitha Valiakalayil, July 2001 - 2007 (MRS and cognition in schizophrenia)
 - (vi) Ms Amy Nash, Dec 2008 – 2010 (early psychosis research)
 - (vii) Ms. Shannon Sears – Dec 2009 – September 2011 (early psychosis research)
 - (viii) Ms. Kim Dillen – March 2010 – March 2012

- (ix) Ms. Chelsea Denaro – September 2011 – August 2013 (early psychosis research)
 - (x) Ms. Michelle Gallant – April 2012 – May 2014 (early psychosis research)
 - (xi) Ms. Emily Keefe – March 12 – present (early psychosis research)
 - (xii) Ms. Heather Moffatt – December 2012 – October 2013 (early psychosis research)
 - (xiii) Ms. Heather Angka – August 2013 – present (early psychosis research)
 - (xiv) Ms. Dana Jakeman – March 2014 – present (early psychosis research)
- (B) Postdoctoral Fellows:
- (i) Dr. Lenka Zedkova, January 2003 - June 2005 (Schizophrenia and fMRI)
 - (ii) *Dr. John Odontiadis, January 2004 - March 2005 (Neurochemistry of schizophrenia and antipsychotics)
 - (iii) *Dr. Christine Mohr, March 2004 - May 2004 (Asymmetrical cerebral contributions to the onset of schizophrenia)
 - (iv) *Dr. Kim Goddard, September 2005 - 2008 (procedural learning skills in schizophrenia via fMRI)
 - (v) Dr. Denise Bernier, September 2008-2011 (4T MRS in first episode psychosis)
 - (vi) Dr. Candice Crocker, December 2012-present (MRS in first episode psychosis)
- (C) M.Sc. Students (Psychiatry, University of Alberta):
- (i) Mr. Daniel Li, September 1999 - January 2002 (D₂SPECT imaging in social phobia)
 - (ii) Ms. Agitha Valiakalayil, September 2004 - 2006 (Proton MRS investigation of glutamate and executive functioning in first episode psychosis).
 - (iii) Dr. Omid Rashidipour, September 2005 - 2006 (Schizophrenia and DTI)
 - (iv) Dr. Harris Lari September 2007- 2009 (Psychiatry outcomes in ER)
- (D) M.Sc. Student (Clinical Investigation Program, Dalhousie University)
- (i) *Dr. Jacob Cooney, 2012-2014 (Multimodal Imaging/Cannabis and Psychosis)
- (E) M.Sc. Students (Biomedical Engineering, University of Alberta):
- (i) *Mr. David McAllindon, January 2006 – 2008 (fMRI in schizophrenia)
- (F) Ph.D. Students (Psychiatry, University of Alberta):
- (i) *Mr. Brent McGrath, September 2003 - May 2008 (Comparison between bipolar and schizophrenic patients on MRS variables)
 - (ii) Ms. Yanina Shulman, September 2003 – November 2007 (Neuroactive steroids in schizophrenia)
 - (v) Ms. Bonnie Lichlyter (Lakusta) September 2006 – 2011 (H-MRS, stimulant addictions and psychosis)
- (G) Ph.D. Students (Clinical Psychology, Comprehensive Research Project, Dalhousie University)
- (i) Kristen Higgins, 2015-present (Cognition and Early Psychosis)
 - (ii) Anne Chinneck, 2015-present (Personality Vulnerability and motives for substance use (alcohol and cannabis) in early psychosis patients)
- (G) Honors in Neuroscience Students:

- (i) Mr. James Purnell, September - December 1999 (Glucose-tolerance testing in schizophrenia - Honors Thesis Supervisor)
 - (ii) Ms. Palka Sawhney, September 2002 - April 2003 (Glutamate in schizophrenia - Honors Thesis)
 - (iii) Mr. Ian Harding, September 2004 - April 2005 (Schizophrenia and fMRI)
 - (iv) Ms. Sanja Kostov, September 2005 - April 2006 (volumetric analysis of the basal ganglia in schizophrenia)
- (H) Psychiatry Residents Rotation (General Adult Psychiatry): (all residents co-supervised)
- (i) Dr. Chantal Moreau (PGY-V) July - October 1999
 - (ii) Dr. Abdulla Al-Mulhim (PGY-III) January - March 1999
 - (iii) Dr. Trevor Prior (PGY-V) April - June 2000
 - (iv) Dr. Daniel Li (PGY-V) July - August 2000
 - (v) Dr. Dave Coulter (PGY-V) April - June 2001
 - (vi) Dr. Kevin Morin (PGY-III) March - June 2003
 - (vii) Dr. Ashfaq Bukhari (PGY-II) September 2005
 - (viii) Dr. Melanie Marsh (PGY-II) November 2005 - February 2006
 - (ix) Dr. Alison Aylot (PGY-I) May 2012-June 2012 (Dal Univ)
- (I) Psychiatry Residents Rotation (Research Elective):
- (i) Dr. Trevor Prior (PGY-III) January - June 1998
 - (ii) Dr. Daniel Li (PGY-III) June - September 1998
 - (iii) Dr. Margaret Mozgala (PGY-I) October 1998
 - (iv) Dr. Ken Joffe (PGY-I) August - September 1999
 - (v) Dr. Atul Khullar (PGY-I) August 1999
 - (vi) Dr. Harris Lari (PGY III) April – September 2008
 - (vii) Dr. Ava Muir (PGY-IV) May 2009 – May 2010 (Dal Univ)
 - (viii) Dr. Jacob Cookey (PGY-I) April 2010 – May 2010(Dal Univ)
 - (ix) Dr. Michael Butterfield (PGY-I) Aug 2011 – Sept 2011 (Dal Univ)
 - (x) Dr. Marie-Claire Bourque (PGY-I) Nov 2011 – Dec 2011 (Dal Univ)
- (J) Summer Research Students:
- (i) Mr. Michael Kroetsch (AHFMR Summer Studentship), May - September 1998 (Obsessive-compulsive symptoms in schizophrenia)
 - (ii) Mr. Andrei Metelitsa, May - September 1999
 - (iii) Ms. Jen Swainson, May - September 2001 (Anxiety disorders in schizophrenia)
 - (iv) Ms. Janna Bentley, June - August 2001 (MRS and neurocognitive assessment in schizophrenia)
 - (v) Mr. Jacques Rizkallah (AHFMR Summer Studentship), May - August 2003 (CCK and schizophrenia)
 - (vi) Ms. Chantelle Tailleir (AHFMR Summer Studentship), May - August 2003 (MRS in first episode schizophrenia)
 - (vii) Ms. Kelly Templeman, May - August 2003 (Psychiatry education research)
 - (viii) Mr. Jeff Bailey, May - August 2004 (Neuroactive steroids in schizophrenia with and without comorbid anxiety)
 - (ix) Ms. Meiling Shih, May - August 2004 (Selective attention and procedural learning in schizophrenia investigated with fMRI)

- (x) Mr. Blake Murdoch, May - August 2005 (Investigation of cognition & glutamate in first episode schizophrenia)
- (xi) Ms. Sanja Kostov, May - August 2005 (Investigation of ¹H-MRS in first episode psychosis)
- (xii) Ms. Sanja Kostov, May - September 2006 (Volumetric analyses of basal ganglia)
- (xv) Mr. Jordan Fisk, May - September 2010 (Tissue type classification of spectroscopic volumes)
- (xvi) Ms. Kristin Higgins, May-August 2012 (Pathways to Care)
- (xvii) Ms. Alisha Hiscott, May-August 2012 (Provincial Standards in Early Psychosis)
- (xviii) Ms. Madison Holmans, May-August 2014 (NSEPP Outcomes in first Episode Psychosis)
- (xix) Ms. Madison Holmans, 2015 (NSPRU Summer Studentship – Cannabis and gender interaction in first episode psychosis)

(K) Student Interns (clinical): (all student interns co-supervised)

	<i>Rotation Dates</i>	<i>Graduating Year</i>
Mabel Mak	March - May 1998	1999
Matthew Watson	August - October 1998	1999
Yasmin Tharani	October - November 1998	1999
Elena Nedeia	November 1998 - January 1999	2000
Michael Yan	March - May 1999	2000
Giang Nguyen	May - July 1999	2000
Twila Burgmann	August - October 1999	2000
Theam Tay	October - November 1999	2000
Chris Murray	December 1999	2000
Dwaine LaRose	November 1999 - January 2000	2001
Suzanne Squires	January - March 2000	2001
Kevin Morin	July - August 2000	2001
Anoo Nijjer	August - October 2000	2001
Lise Warmington	October - November 2000	2001
Kellie Waters	November - December 2000	2001
Matthew Morgan	December 2000	2001
Tony Yang	January 2001	2001
Samir Patel	July - August 2000	2001
Rob Wilson	March - May 2000	2001
Angelova Jordanka	March 2001	2002
Fan-Hsia Mang	April - June 2001	2002
Paul Soper	August 2001	2002
Helen Yeung	September - October 2001	2003
Kathryn Fung	November 2001	2002
Carlo Panaro	December 2001 - Jan 2002	2003
Ryan Wright	April - June 2002	2003
Jeffrey Beitel	October - November 2002	2003
Joseph Pagano	November - December 2002	2003
Janna Bentley	March - April 2002	2003
Adam Romanovsky	January - March 2002	2003
Artur Szymczak	December 2002 - Jan 2003	2004
Charlotte Ballermann	March - April 2003	2004

Jacques Rizkallah	October - Nov 2003	2006
Andrew Robertson	October - Dec 2003	2006
Candace Walker	March - April 2004	2005
Angie Paulson	Nov-December 2005	2008

* At Dalhousie University, Clinical Clerks are assigned to the Nova Scotia Early Psychosis Program (NSEPP) and the team (including Dr. Phil Tibbo) supervise the students.

GRADUATE STUDENT COMMITTEES

Examiner -MSc Thesis Defense Committee - Wendy Chrapko (Psychiatry). September 22, 2003 – University of Alberta (UofA).

Examiner - PhD Thesis Defense Committee - Florin Dolcos (Neuroscience). September 20, 2004 – University of Alberta (UofA).

Examiner -PhD Candidacy Examination Committee - Jeff Armstrong (Psychiatry). October 3, 2005 – University of Alberta (UofA).

Examiner -PhD Candidacy Examination Committee – Dave Hayes (Psychiatry). March 10, 2006 – University of Alberta (UofA).

Examiner -PhD Candidacy Examination Committee – Yanina Shulman (Neuroscience). April 18, 2006 – University of Alberta (UofA).

Examiner -MSc Thesis Defense Committee – Agitha Valiakalayil (Psychiatry). July 21st, 2006 – University of Alberta (UofA).

Examiner - PhD Candidacy Examination Committee – Emily Bell (Psychiatry). August 11th, 2006 – University of Alberta (UofA).

Examiner -PhD Thesis Defense Committee – Brent McGrath (Psychiatry). August 14th, 2006 – University of Alberta (UofA).

Examiner - PhD Thesis Defense Committee – Emily Bell (Psychiatry). August 23, 2007 – University of Alberta (UofA).

Examiner -PhD Thesis Defense Committee – Yanina Jackson (Neuroscience) October 1st, 2007 – University of Alberta (UofA).

Examiner - MSc Thesis Defense Committee – Neha Bhatra (Psychiatry) October 2007 – University of Alberta (UofA).

Examiner - MSc Thesis Defense Committee – David McAllindon (Biomedical Engineering) October 2008 – University of Alberta (UofA).

Examiner - PhD Candidacy Examination – Bonnie Lichlyter (Psychiatry) February 2009 – University of Alberta (UofA).

External Examiner – PhD Thesis – Lauren Christine Bresee (Public Health and Epidemiology) June 2010 – University of Alberta (UofA).

Examiner – PhD Defense Committee – Bonnie Lichlyter (Lakusta) (Psychiatry) December 2011 – University of Alberta (UofA).

External Examiner – PhD Exam – Cindy Hovington (Neuroscience) September 2013 – McGill University.

Examiner – MSc Thesis Defense Committee – Jacob Cookey (CIP). August 2014- Dalhousie University.

RESEARCH AND GRANTS

CLINICAL TRIALS (Industry funded)

Principal Investigator:

GAL-SCH-201 Phase II-Schizophrenia Protocol A study of galantamine Hbr as an adjunctive treatment to risperdal in male outpatients with schizophrenia and associated cognitive deficits. (Final Protocol) **Janssen**

R092670-PSY-3002 Schizophrenia Protocol. A randomized, double-blind, parallel-group, comparative study of flexibly dosed paliperidone palmitate (3 doses) administered every 4-weeks and flexibly dosed Risperdal Consta (25, 37.5 or 50 mg) administered every 2 weeks in subjects with symptomatic schizophrenia. **Janssen**

Co-Investigator:

A1281173 A one year, phase IV, open label, non-comparative trial of the effect of Ziprasidone HCL on metabolic syndrome risk factors in patients with psychotic disorders. **Pfizer**

99769 GAD Study A double-blind, randomized, placebo-controlled, multicentre relapse prevention trial with 20 mg of escitalopram in patients with GAD. **Lundbeck**

99908 A pharmaco-economic piggyback study of clinical trial 99769 evaluating the cost structure of treatment and the cost drivers of GAD and the economic impact of escitalopram. **Lundbeck**

BN 1 6568B A phase-II multicentre, placebo and paroxetine controlled, double-blind, randomized study on the efficacy and safety of a NK1 antagonist in patients with major depressive disorder (MDD)(Ro 67-5930 in major depressive disorder a placebo and paroxetine-controlled study of efficacy and safety). **Hoffman-LaRoche**

RIS-INT-63 Risperidone depot (microspheres) in the treatment of subjects with schizophrenia or schizoaffective disorder - an open label follow-up trial of RIS-INT-57 and RIS-INT-61. **Janssen**

A1281024 Open extension study evaluating the safety and tolerability of oral ziprasidone in the treatment of patients who have successfully completed a previous ziprasidone study. **Pfizer**, 2002-2004

99775 A double-blind, randomized, placebo and active comparator referenced, randomized, parallel-group, phase III study of gaboxadol in non-elderly patients with primary insomnia: A 2-week outpatient study. **Lundbeck**

99896 A pharmaco-economic piggyback study of clinical trial 99775 evaluating the cost structure of treatment, the cost drivers and assessing quality of life for patients with primary insomnia. **Lundbeck**

RIS-BIP-301 A randomized open-label trial of Risperdal Consta versus oral antipsychotic care in subjects with bipolar disorder. **Janssen**

0858A4-316-NA A multicentre, randomized, double-blind, placebo-controlled study of a combination of levonorgestrel and ethinyl estradiol in a continuous daily regimen in subjects with premenstrual dysphoric disorder. **Wyeth-Ayerst**

CXBD173A2204 A randomized double-blind, placebo-controlled, parallel-group study of the efficacy, safety and tolerability of XBD173 in patients with GAD. **Novartis**

C6671/3030/AX/US A 10-week, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Gabitril at 4, 8, and 12 mg/day in the treatment of adults with GAD. **Cephalon**

C6671/3033/AX/US A 12-month, open-label, flexible-dosage study to evaluate the safety and efficacy of Gabitril treatment (up to 16 mg/day) in adults with GAD. **Cephalon**

IR076477SCH4016 (PILAR) Pharmacoepidemiological International Longitudinal Antipsychotic Registry. **Janssen Ortho**

R092670-SCH-3004 A prospective, randomized, active-controlled, rater-blinded study of the prevention of relapse comparing paliperidone palmitate with oral risperidone in adults with recently-diagnosed schizophrenia who are at high risk of relapse. **Janssen Ortho**

A1281173 A one year, Phase IV, open label, non-comparative trial of the effect of ziprasidone HCL on metabolic syndrome risk factors in patients with psychotic disorders. **Pfizer**

RO4917838 A 24 week, Phase III, multi-center, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period. **Hoffman Roche**

RO4917838 A 12 week, Phase III, multi-center, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of in patients with sub optimally controlled symptoms schizophrenia treated with antipsychotics followed by a 40 week, double-blind parallel-group, placebo controlled treatment period. **Hoffman Roche**

PEER-REVIEWED RESEARCH GRANTS

- 1998-2001 National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD) Young Investigators Award. (PI) Magnetic resonance spectroscopy of family members with schizophrenia. Young Investigators Award (2-year with one year extension granted to 2002). Total Amount: \$53,940.
- 1998-1999 Canadian Psychiatry Research Foundation (CPRF). (PI) Magnetic resonance spectroscopy of family members with schizophrenia. (1-year). Total Amount: \$25,000 - Declined.
- 1999 University of Alberta Hospital Foundation/Alberta Health Sciences Research Institute. (PI) Dopamine and social phobia: a SPECT study using ¹²³I-Epididone and ¹²³I-betaCIT. (1-year). Total Amount: \$13,500.
- 1997-2000 Alberta Heritage Foundation for Medical Research (AHFMR). (PI) Magnetic resonance spectroscopy of family members with schizophrenia. Clinical Fellowship Award (3-years). Total Amount: \$42,000.
- 2000-2001 University of Alberta Hospital Foundation/Alberta Health Sciences Research Institute. (Co-Investigator) Iomazenil SPECT study of central GABA (A)/benzodiazepine receptor binding in women with premenstrual dysphoric disorder (PMDD). (2-years). Total Amount: \$40,000.
- 1999-2001 Intellectual Infrastructure Partnership Program (IIPP)/Canada Foundation for Innovation (CFI) and other sources. (Co-Investigator) Western Canadian Centre for Biomedical Applications of Nuclear Magnetic Resonance. (2-years). Total Amount: \$>12M.
- 1999-2002 Medical Research Council of Canada (MRC). (Co-Investigator) Brain GABA in Healthy Volunteers. (3-years). Total Amount: \$51,309.
- 2002-2003 Edmonton Civic Employees Charitable Assistance Fund. (Co-Investigator) Perceptions of intimidation vs. expectations in undergraduate medical education. (1-year). Total Amount: \$2,280.
- 2002-2004 University of Alberta Hospital Foundation (UAHF). (PI) The investigation of CCK in individuals comorbid in schizophrenia and anxiety disorders. (1-year with one year extension granted to 2003). Total Amount: \$22,500.
- 2001-2004 Alberta Heritage Foundation for Medical Research (AHFMR). (PI) Magnetic resonance spectroscopy and cognitive assessment in individuals at risk for schizophrenia. Clinical Investigator Award (3-years with six month extension granted to December 31, 2004). Total Amount: \$150,000.
- 2001-2004 National Alliance for Research of Schizophrenia and Affective Disorders (NARSAD). (PI) Proton magnetic spectroscopy and neuropsychological

- investigation in a genetic high risk paradigm. (2 years with a one year extension granted to December 31, 2004). Total Amount: \$61,060.
- 2002-2005 Zyprexa Research Foundation. (Co-Investigator) Neuropsychological changes after 12-months treatment of early phase schizophrenia with random assignment open-label olanzapine, risperidone, or quetiapine. (3-years). Total Amount: \$144,000.
- 2004-2005 University Hospital Foundation (UHF). (PI) Investigation of ¹H-MRS glutamate in first-episode schizophrenia. (1-year - January 1, 2004 to August 31, 2005 [8-month extension]). Total Amount: \$22,500.
- 2004-2007 Canadian Institutes of Health Research (CIHR). (PI) High field strength proton-MRS investigation of *in vivo* brain glutamate and its modulation with pharmacotherapy in first episode schizophrenia. (3-years - October 1, 2004 to September 30, 2007), Total Amount: \$267,486.
- 2004-2006 Canadian Psychiatric Research Foundation (CPRF). (PI) Investigation of CCK and neuroactive steroids in individuals comorbid with schizophrenia and anxiety. (2-years- September 1, 2004 to August 31, 2005), Total Amount: \$79,585.60.
- 2005 University Hospital Foundation (UHF). (PI) Investigation of the kynurenine pathways in schizophrenia. (1 year: Jan 1, 2005 to Dec 31, 2005), \$8,383.
- 2005 University Hospital Foundation (UHF). (PI - Dr. D. Cox) Analysis of a candidate gene as a cause of schizophrenia. 1 year: Jan 1, 2005 to Dec 31, 2005, \$22,496.
- 2005-2008 Alberta Heritage Foundation for Medical Research (AHFMR) Clinical Investigator Renewal. High field strength proton-MRS investigation of *in vivo* brain glutamate and its modulation with pharmacotherapy in first episode schizophrenia. (3 years - July 1, 2005 to June 30, 2008), Salary Award.
- 2006 University Hospital Foundation (UHF). (PI) Investigation of procedural learning with fMRI in first episode schizophrenia neurodevelopmental implications (1-year - January 1 - December 31, 2006), Total Amount: \$20,799
- 2006-2008 Canadian Psychiatric Research Foundation (CPRF). (Co-Investigator) NPAS3, encoding a brain transcription factor as a causative gene for schizophrenia. Total Amount: \$200,000.
- 2007 University Hospital Foundation (UHF). (PI) MRS Drugs of abuse in first episode schizophrenia – (1 year – January 2007 to December 2007) Total Amount: \$15,937.
- 2007 Alberta Heritage Foundation for Medical Research (AHFMR) Multiuser Equipment Grant. (Co-user) Open RF head coil for 4.7T. Total amount: \$80,000
- 2008-2011 The Faculty of Medicine and Dentistry and Capital Health Emerging Research Teams Grant (PI) Improving outcomes in first episode schizophrenia: an education and genetic focused approach. (3 years - total amount: \$300,000)

- 2008-2011 Dalhousie Department of Psychiatry Research Fund (Co-Applicant). Metformin for Antipsychotic Weight Gain. A Pragmatic Randomized Controlled Trial. (3 years – total amount: \$10,000)
- 2009-2011 Nova Scotia Health Research Foundation (NSHRF), Development/Innovation Grant. 2009 (PI) Development and preliminary testing of in vivo localized proton magnetic resonance spectroscopy at 4 Tesla. (1 year) Total Amount \$14,000
- 2009-2010 Dalhousie Department of Psychiatry Research Fund (DPRF). 2009 (Co-Inv) Changes in family appraisal, level of distress and knowledge associated with two modes of family education in Early Psychosis: A pilot study. (1 year) Total Amount \$10,000
- 2009-2012 Canadian Institutes of Health Research (CIHR). (Co-PI) NPAS3 variants in schizophrenia and other psychoses. (3 years) Total amount: \$205,859
- 2009-2011 Dalhousie Department of Psychiatry Research Fund. 2009 (Co-PI) Quantitative Proton Spectroscopy of White Matter at 4 Tesla in First Episode Schizophrenia Total amount: \$10,000
- 2010 Capital Health Research Fund. 2010 (PI) Help Seeking Pathways in First Episode Psychosis: A Capital Health Regional Pilot Study. (1 year) \$13,203.80
- 2010-2011 Dalhousie Department of Psychiatry Research Fund. 2010 (Co-Inv). Long Term Outcomes in Early Psychosis. (1 year) Total amount: \$9,930
- 2010-2013 Canadian Institutes of Health Research (Operating Grant) Regional Partnership Program. (Co-Inv.) Understanding reward motivation and expectancy in early phase psychosis smokers: a neuroimaging and genetic approach. (2 years) Total amount: \$402,329
- 2010-2013 Canadian Institutes of Health Research (Operating Grant). (PI) Quantitative proton spectroscopy of white matter at 4 Tesla in first-episode psychosis part II: A clinical study. (3 years) Total amount: \$186,963
- 2010 Category A Research Grant (IWK Hospital) January 2010 (Co-Inv). Cognitive and Psychosocial Functioning in Adolescents and Young Adults at Ultra High Risk for Psychosis. Total amount: \$4,000.
- 2011 Dalhousie Department of Psychiatry Research Fund. 2010 (PI). NPAS3 variants in Schizophrenia: a neuroimaging study. (1 year) Total amount: \$9,750
- 2011 Canadian Institutes of Health Research (CIHR) Meeting, Planning and Dissemination, Planning Grants. 2011 (Co-Inv). Sustaining Recovery: Supporting the Transition from Specialized Services to Primary Care for At-Risk Youth Who Have Experienced a First Episode of Psychosis. Total amount: \$23,800 (over 1 year: Feb 2011 to Feb 2012).

- 2011 Dalhousie Department of Psychiatry Research Fund (Co-Inv). The topical niacin skin flush test: Development of procedures and collection of normative data. Total amount: \$10,000
- 2011 Dalhousie Department of Psychiatry Research Fund (Co-Inv). Memory for serial order in schizophrenia. Total amount: \$9,716
- 2011 Dalhousie Department of Psychiatry Research Fund (Co-Inv). Mindfulness-based support group for family members: a feasibility study. Total amount: \$8,560
- 2012-2015 Nova Scotia Health Research Foundation (PI). NPAS3 variants in schizophrenia: a neuroimaging study. Total amount: \$149,836 (3 years).
- 2012 Dalhousie Department of Psychiatry Research Fund (Co-Inv). Auditory change detection and auditory hallucinations in early phase psychosis. Total amount: \$9,562
- 2013-2018 Canadian Institutes of Health Research/Nova Scotia Health Research Foundation (Co-Inv). Opportunities for very early intervention in youth at high risk for severe mental illness. Total amount: \$338,633 (5 years)
- 2013 Dalhousie Department of Psychiatry Research Fund (Co-Inv). Multimodal neuroimaging of white matter microstructure in early phase psychosis: the impact of early adolescent cannabis use. Total amount: \$10,000
- 2013 Dalhousie Department of Psychiatry Research Fund (Co-Inv). Neurological soft signs in psychosis: the impact of NPAS3 gene variants on cerebellar structural and functional abnormalities. Total amount: \$8,654
- 2013 Dalhousie Department of Psychiatry Research Fund (Co-Inv). Claymation art therapy as adjunctive treatment to promote recovery in early psychosis: A pilot project. Total amount: \$9,540 (1 year)
- 2013-2016 Canadian Institutes of Health Research/Partnership for Health System Improvement (Co-Inv). Sustaining Recovery: Supporting the Transition from Specialized Services to Community-based Primary Care for At-Risk Youth who have Experienced Early Psychosis. Total amount: \$599,987 (3 years)
- 2013-2016 Nova Scotia Health Research Foundation (Co-Inv). Cognitive-behavioral therapy for psychotic-like experiences and basic symptoms in children and adolescents: a pilot randomized-controlled trial. Total amount: \$147,275 (3 years)
- 2013 Nova Scotia Health Research Foundation (PI). [Knowledge Sharing Award] Early and Optimal Treatment of Mental Disorder Involving Psychosis: Major findings for key stakeholders. Total amount: \$10,000 (1 year)

- 2015 Nova Scotia Health Research Foundation (PI). [Knowledge Sharing Award] Key findings in Early Psychosis; Knowledge sharing initiative Year 2. Total amount: \$10,000 (1 year)
- 2015 Nova Scotia Health Authority/QEII Foundation, Translating Research into Care (TRIC) Health Improvement Level 1, (Co-PI) Sustaining clinical gains for young adults with psychosis transitioning from specialized to community mental health care. Total amount: \$2887.62
- 2015 Dalhousie Department of Psychiatry Research Fund (Co-Inv). The experience of mindfulness and recovery: A Qualitative study. Total amount: \$9,100
- 2015 Dalhousie Department of Psychiatry Research Fund (Co-Inv). Assessment of frontal white phospholipid metabolism in early phase schizophrenia: A localized ³¹P MRS study. Part 1: Testing the methodology with controls. Total amount: \$9,360
- 2015 Dalhousie Department of Psychiatry Research Fund (Co-Inv). The Impact of Caffeine on Cognition in Schizophrenia. Total amount: \$9,776
- 2016 Dalhousie Department of Psychiatry Research Fund (PI). Engagement to Early Intervention Services for Psychosis: Investigation of rates and associated factors. Total amount: \$9,950
- 2016 Dalhousie Department of Psychiatry Research Fund (Co-Inv). Personality vulnerability and motives for substance abuse (alcohol and cannabis) in early psychosis patients. Total amount: \$9,951
- 2016 Mental Health Foundation of Nova Scotia (PI). Youth and Cannabis: Addressing the Myths. Total amount: \$19,425
- 2016 Nova Scotia Health Authority/QEII Foundation, Translating Research into Care (TRIC) Healthcare Improvement Level 3, (Co-PI) An investigation of the effectiveness of peer support interventions on transitions from a specialized first episode psychosis program to community mental health care. Total amount: \$59,545
- 2016 Nova Scotia Health Authority Research Fund (Co-Inv). An investigation of sex as a mediating factor of the auditory mismatch negativity's utility as a biomarker in early-phase psychosis. Total amount: \$14,970

PEER-REVIEWED RESEARCH GRANTS (APPLIED)

- 2016 Dalhousie Department of Psychiatry Research Fund (Co-Inv). Microstructural Changes in Frontal White Matter Associated with Cannabis Use in Early Phase Psychosis: A Diffusion Tensor Imaging (DTI) and Relaxometry Study.
- 2016 Nova Scotia Health Research Fund Knowledge Translation Grant (Co-Inv). Weeding out the Myths.

2016 Canadian Institute of Health Research Project Scheme Grant (PI). Cannabis effects on white matter microstructure and outcomes in early phase psychosis: a 1 year dual site longitudinal study.

NON-PEER REVIEWED RESEARCH GRANTS

2009-2011 Schizophrenia Society of Canada. 2009 (Co-Inv). Understanding the Link between Cannabis Use and Psychosis: A National Awareness Strategy for Youth at Risk. Total amount: \$856,370

2010-2012 Nova Scotia Department of Health. July 2010. (Co-PI). “Your Mind Matters”: A Young Adult Community Education Project. Total amount: \$25,000 over 2 years.

2010-2015 Private Donor. (Associate Investigator). A one year randomized, controlled, open-label study of the impact of flexible doses of niacin (Niaspan FCT) as an adjunct to antipsychotic medication in the treatment of first episode psychosis. (5 years). Total amount: \$895,049

PRINCIPAL RESEARCH INTERESTS

1. Magnetic resonance spectroscopy (MRS), fMRI and diffusion tensor imaging (DTI), and neuropsychological evaluations in individuals with first-episode psychosis/schizophrenia and family members.
2. Adolescents at risk for schizophrenia and first-episode psychosis.
3. Addictions and first-episode psychosis
4. Genetics and epigenetics of psychosis
5. Pathways to care in first episode psychosis

REVIEWS

Invited Journal Reviewer:

- < Canadian Journal of Psychiatry
- < Schizophrenia Research
- < Journal of Psychiatry and Neuroscience
- < Psychiatric Research
- < Neuropsychopharmacology
- < Archives of General Psychiatry
- < Progress in Neuro-Psychopharmacology & Biological Psychiatry
- < Academic Psychiatry
- < Acta Psychiatrica Scandinavica
- < Schizophrenia Bulletin
- < The International Journal of Neuropsychopharmacology

Invited Book Reviewer:

- < *Images in Psychiatry: Canada*. Quentin Rae-Grant, Editor. Book Review for the *American Journal of Psychiatry*. 155(4): 573-574, 1998.

Invited Research Grant Reviewer:

- < University of Alberta Hospital Foundation/Alberta Health Sciences Research Institute.
- < Canadian Institutes of Health Research (CIHR) External Grant Reviewer.
- < Alberta Heritage Foundation for Medical Research (AHFMR) Fellowship & Studentship Awards.
- < Multiple Sclerosis Society of Canada.
- < Manitoba Mental Health Research Council.
- < Department of Psychiatry Research Fund (DPRF) Dalhousie University, Halifax
- < Medical Research Council (MRC), UK

Invited External Referee:

- < Faculty Promotions and Reappointment Committees: Dalhousie University; University of Toronto; University of Ottawa; McGill University; University of British Columbia.
- < Clinical Diagnostics and Research Centre - AHE Funding Review, Capital Health, Alberta.

Invited Abstract Reviewer:

- < Scientific abstracts for Canadian Psychiatric Association Annual Conference

PUBLICATIONS AND ACADEMIC RESEARCH COMMUNICATIONS

A) Papers, refereed (70):

1. Bärlocher F., **Tibbo P.G.**, Christie S. (1989). Formation of phenol-protein complexes and their use by two stream invertebrates. *Hydrobiologia* 173: 243-249.
2. **Tibbo P.**, Silverstone P., McEwan A.J.B., Scott J., Joshua A., Goldberg K. (1997). A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with ¹²³I-epidepride in patients with schizophrenia and controls. *Journal of Psychiatry and Neuroscience* 22: 39-45.
3. **Tibbo P.**, Nopoulos P., Arndt S., Baily J., Andreasen N. (1998). Corpus callosum shape and size morphology in male schizophrenics. *Biological Psychiatry* 44: 405-412.

4. **Tibbo P.**, Gendemann K. (1999). Improvement of obsessions and compulsions with clozapine in an individual with schizophrenia. *Canadian Journal of Psychiatry* 44(10): 1050-1051 (letter).
5. **Tibbo P.**, Warneke L. (1999). Obsessive-compulsive disorder in schizophrenia: epidemiologic and biological overlap. *Journal of Psychiatry and Neuroscience* 24(1): 15-24.
6. **Tibbo P.**, Chue P.S., Wright E. (1999). Hospital use following assertive community treatment (ACT) in Edmonton, Alberta. *Canadian Journal of Psychiatry* 44: 276-279.
7. Prior T., Chue P.S., **Tibbo P.**, Baker G.B. (1999). Drug metabolism and atypical antipsychotics. *European Neuropsychopharmacology* 9(4): 301-309.
8. Asghar S.J., Chue P.S., Coupland N.J., **Tibbo P.** (1999). Polyglandular Autoimmune Syndrome type II and paranoid schizophrenia with obsessive-compulsive disorder. *Canadian Journal of Psychiatry* 44(4): 391-392 (letter).
9. **Tibbo P.**, Kroetsch M., Chue P., Warneke L. (2000). Obsessive-compulsive disorder in schizophrenia. *Journal of Psychiatric Research* 34: 139-146.
10. Prior T., Chue P.S., **Tibbo P.** (2000). Investigation of Turner's Syndrome in schizophrenia. *Neuropsychiatric Genetics* 96: 373-378.
11. **Tibbo P.**, Hanstock C.C., Asghar S., Allen P. (2000). Proton magnetic resonance spectroscopy (H-MRS) of the cerebellar vermis in male schizophrenics. *Journal of Psychiatry and Neuroscience* 25(5): 509-512.
12. Khullar A., Chue P., **Tibbo P.** (2001). Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. *Journal of Psychiatry and Neuroscience* 26(1): 55-59.
13. **Tibbo P.**, Joffe K., Chue P., Metelitsa A., Wright E. (2001). Global assessment of functioning following assertive community treatment in Edmonton, Alberta: a longitudinal study. *Canadian Journal of Psychiatry* 46: 144-148.
14. Li D., Chokka P., **Tibbo P.** (2001). Towards an integrative understanding of social phobia. *Journal of Psychiatry and Neuroscience* 26(3): 190-202.
15. **Tibbo P.**, de Gara C.J., Blake T.M., Steinberg C., Stonehocker B. (2002). Perceptions of intimidation in the psychiatric educational environment in Edmonton, Alberta. *Canadian Journal of Psychiatry* 47(6): 562-567.
16. **Tibbo P.**, Swainson J., Chue P., Le Mellédo J-M. (2003). Prevalence of relationship to delusions and hallucinations of anxiety disorders in schizophrenia. *Depression and Anxiety* 17(2): 65-72.

17. **Tibbo P.**, Hanstock C., Valiakalayil A., Allen P. (2004). 3T proton MRS investigation of glutamate and glutamine in genetic high-risk adolescents for schizophrenia. *American Journal of Psychiatry* 161(6): 1116-1118.
18. Valiakalayil A., Paulson L.A., **Tibbo P.** (2004). Burden in adolescent children of parents with schizophrenia: the Edmonton high risk project. *Social Psychiatry and Psychiatric Epidemiology* 39(7): 528-535.
19. **Tibbo P.**, Templeman K. (2004). The RCPSC Oral Examination: patient perceptions and impact on participating psychiatric patients. *Canadian Journal of Psychiatry* 49(7):480-486.
20. Chue P., **Tibbo P.**, Wright E., Van Ens J. (2004). Client and community services satisfaction with an assertive community treatment subprogram for inner-city clients in Edmonton, Alberta. *Canadian Journal of Psychiatry* 49(9):621-624.
21. McGrath B.M., Silverstone P.H., **Tibbo P.** (2005). Self-reported health status and quality of life among full-time students attending the University of Alberta. *University of Alberta Health Sciences Journal* 2(1):8-11.
22. Shulman Y., **Tibbo P.** (2005). Neuroactive steroids in schizophrenia. *Canadian Journal of Psychiatry* 50(11):695-702.
23. Shulman Y., **Tibbo P.** (2005). GABAergic deficits in schizophrenia: Evidence and implications. *University of Alberta Health Sciences Journal* 2(2):23-27.
24. Shulman, Y., Grant, S., Seres, P., Hanstock, C., Baker, G.B., and **Tibbo, P.** (2006). The relationship between peripheral and central glutamate and glutamine levels. *Journal of Psychiatry and Neuroscience* 31(6):406-410.
25. Grant, S., Shulman, Y., **Tibbo, P.**, Hampson, D., Baker, G. (2006). Determination of D-serine and related neuroactive amino acids in human plasma by high performance liquid chromatography with fluorimetric detection. *Journal of Chromatology B* 844(2):278-282.
26. Zedkova, L., Woodward, N., Harding, I., **Tibbo, P.**, Purdon, S. (2006). Procedural learning in schizophrenia investigated with functional magnetic resonance imaging. *Schizophrenia Research* 88:198-207.
27. Woodward N, **Tibbo P**, Purdon S. (2007). An fMRI investigation of procedural learning in unaffected siblings of patients with schizophrenia. *Schizophrenia Research* 94:306-16.
28. McGrath, BM., **Tibbo, P.** (2007) Perceived stigma toward mental health consumers does not influence willingness to seek mental health care nor psychiatry as a top residency choice among psychiatrically-minded 1st and 4th year medical students. *Dalhousie Medical Journal* 34(3): 9-13

29. Batra, N., Seres-Mailo, J., Hanstock, C., Seres, P., Allen, P., Khudabux, J., Bellavance, F., Baker, G., **Tibbo, P.**, Hui, E., Le Melledo, J-M. (2008). ¹H MRS measurement of brain glutamate levels in premenstrual dysphoric disorder. *Biological Psychiatry* 63(12):1178-84
30. Purdon, S.E., Valiakalayil, A., Hanstock, C., Seres, P., and **Tibbo, P.** (2008). Elevated ³T proton MRS glutamate levels associated with poor continuous performance test (CPT-0X) scores and genetic risk for schizophrenia. *Schizophrenia Research* 99:218-224
31. Choi, C., Bhardwaj P., Seres P., Kalra, S., **Tibbo, P.**, Coupland, N. (2008). Measurement of glycine in human brain by triple refocusing ¹H-MRS in vivo at 3.0T. *Magnetic Resonance in Medicine* 59(1):59-64
32. Lichlyter, B., Purdon, S., **Tibbo, P.** (2009). Reviewing the Dangers of Methamphetamine: A Brain Imaging-Focused Literature Review. *University of Alberta Health Sciences Journal* 5(1):18-23.
33. Woodward, N., Waldie, B., Rogers, B., **Tibbo, P.**, Seres, P., Purdon, S. (2009). Abnormal prefrontal cortical activity and connectivity during response selection in first episode psychosis, chronic schizophrenia, and unaffected siblings of individuals with schizophrenia. *Schizophrenia Research* 109(1-3):182-90.
34. McAllindon, D.P., Wilman, A.H., Purdon, S.E., **Tibbo, P.G.** (2010). Functional MRI of Choice Reaction Time in Chronic Schizophrenia and First-Degree Relatives. *Schizophrenia Research* 120:232-233.
35. Macintyre, G., Alford, T., Xiong, L., Rouleau, G.A., **Tibbo, P.G.**, and Cox, D.W. (2010). Association of NPAS3 exonic variation with schizophrenia. *Schizophrenia Research* 120:143-149.
36. Good, K.P., **Tibbo, P.**, Milliken, H., Whitehorn, D., Alexiadis, M., Robertson, N., Kopala, L.C. (2010). An investigation of a possible relationship between olfactory identification deficits at first episode and four-year outcomes in patients with psychosis. *Schizophrenia Research* 124: 60-65.
37. Swainson, J., Marsh, M., **Tibbo, P.** (2010). Psychiatry Residents as Teachers: Development and Evaluation of a teaching manual. *Academic Psychiatry* 34(4):305-309.
38. Lichlyter, B., Purdon S., **Tibbo, P.** (2011). Predictors of psychosis severity in individuals with primary stimulant addictions. *Addictive Behaviors* 36 (1-2):137-139.
39. Purdon SE, Waldie B, Woodward ND, Wilman AH, **Tibbo PG** (2011). Procedural learning in first episode schizophrenia investigated with functional magnetic resonance imaging. *Neuropsychology* 25(2):147-158.
40. **Tibbo, P.**, Bernier, D., Hanstock, C.C., Seres, P., Lakusta, B., Purdon, S. (2013) ³-T proton magnetic spectroscopy in unmedicated first episode psychosis: A focus on creatinine. *Magnetic Resonance in Medicine* 69:613-620.

41. McGrath B, **Tibbo P.** (2012) Perception of stigma toward mental health consumers and willingness among Canadian university students to seek mental health. *Stigma Res and Action* (accepted)
42. Malla A, **Tibbo P,** Chue P, Levy E, Manchanda R, Teehan M, Williams R, Iyer S, Roy M. (2013) Long-acting injectable antipsychotics: Recommendations for clinicians. *Can J Psychiatry* 2013;58 (5 Suppl 1):30S-35S.
43. Iyer S, Banks N, Roy M, **Tibbo P,** Williams R, Manchanda R, Chue P, Malla A. (2013) A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I – Patient Perspectives. *Can J Psychiatry* 2013;58 (5 Suppl 1):14S-22S.
44. Iyer S, Banks N, Roy M, **Tibbo P,** Williams R, Manchanda R, Chue P, Malla A. (2013) A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part II – Physician perspectives. *Can J Psychiatry* 2013;58 (5 Suppl 1):23S-29S.
45. Manchanda R, Chue P, Malla A, **Tibbo P,** Roy M, Williams R, Iyer S, Lutgens D, Banks N. (2013) Long-acting injectable antipsychotics: Evidence of effectiveness and use. *Can J Psychiatry* 2013;58 (5 Suppl 1):5S-13S
46. Bernier D, Coockey J, McAllindon D, Bartha R, Hanstock CC, Newman AJ, Stewart S, Crocker C, Good K, **Tibbo P.** (2013) Multimodal neuroimaging of frontal white matter microstructure in early phase schizophrenia: the impact of early adolescent cannabis use. *BMC Psychiatry* 2013, 13:264.
47. Crocker CE, Bernier D, Hanstock C, Lakusta B, Purdon SE, Seres P, **Tibbo PG.** (2014) Prefrontal glutamate levels in early phase schizophrenia and abstinent methamphetamine addiction: A ¹H-MRS study at 3 Tesla. *Schizophrenia Research* 2014 Aug; 157 (1-3):231-7.
48. Coockey J, Bernier D, **Tibbo P.** (2014) White matter changes in early phase psychosis and cannabis use: an update and systematic review of diffusion tensor imaging studies. *Schizophrenia Research* 2014 Jul; 156(2-3):137-42.
49. Bernier D, Macintyre G, Bartha R, Hanstock CC, McAllindon D, Cox D, Purdon S, Aitchison KJ, Rusak B, **Tibbo PG.** (2014) NPAS3 Variants in Schizophrenia: A Neuroimaging Study. *BMC Medical Genetic* 2014; 15:37.
50. **Tibbo P.** (2014) The brains of youth harmed by cannabis. *The Chronicle of Neurology + Psychiatry*, 17(5) pg 3. (Invited guest editorial)
51. **Tibbo P,** Malla A, Manchanda R, Williams R, Joobar R. (2014) Relapse Risk Assessment in Early Phase Psychosis: The Need for a Reliable and Valid Tool. *Canadian Journal of Psychiatry* 2014; 59(2):655-658.
52. Rudolph E, Ells E, Campbell D, Abriel S, **Tibbo P,** Salisbury D, Fisher D. (2015) Finding the missing-stimulus mismatch negativity (MMN) in Early Psychosis: Altered MMN to

- violations of an auditory gestalt. *Schizophrenia Research* 166 (2015) 158-163.
53. Crocker C, **Tibbo P**. (2015) Cannabis and the maturing brain: Role in psychosis development. *Clin Pharmacol Ther*. 2015 Jun; 97(6):545-7.
 54. **Tibbo P**. (2015) Identifying and Assessing Barriers to Optimal Outcomes for Psychosis: An important research focus. *The Canadian Journal of Psychiatry*. 60(8):1-2.
 55. Nolan M, Malla A, **Tibbo P**, Ross N, Abdel-Baki A. (2016) Early Intervention for Psychosis in Canada: What is the State of Affairs? *Canadian Journal of Psychiatry*. 61(3):186-194.
 56. Aydin C, **Tibbo P**, Ursuliak Z. (2016) Psychosocial Interventions in Reducing Cannabis Use in Early Phase Psychosis: A Canadian Survey of Treatments Offered. *The Canadian Journal of Psychiatry*. June 2016. 61(6):367-372.
 57. Bernier D, Bartha R, McAllindon D, Hanstock C, Marchand Y, Dillen KN, Gallant M, Good KP, **Tibbo P**. (2016) Illness versus substance use effects on frontal white matter in early phase schizophrenia: A 4 Tesla (1) H-MRS study. *Schizophrenia Research*. August 2016. 175(1-3):4-11.
 58. Gardner D, Abidi S, Ursuliak Z, Morrison J, Teehan M, **Tibbo P**. (2015) Incidence of oculogyric crisis and long term outcomes with second-generation antipsychotics in a first-episode psychosis program. *Journal of Clinical Psychopharmacology*. 35(6):715-718.
 59. Williams R, Malla A, Roy MA, Joober R, Manchanda R, **Tibbo P**, Banks N, Agid O. (2015) What is the place of Clozapine in the treatment of early psychosis in Canada? *The Canadian Journal of Psychiatry*. 62(2):109-114.
 60. Lal S, Marandola G, Theriault J, **Tibbo P**, Manchanda R, Williams R, Joober R, Banks N, Malla A. (2016) "Worried about relapse": Family members' experiences and perspectives of relapse in first-episode psychosis. *Early Intervention in Psychiatry*. Early Intervention in Psychiatry. February 2017 DOI: 10.1111/eip.12440.
 61. McAllindon D, **Tibbo P**, Eskes G. (2016) Is Performance on Probed Serial Recall Tasks in Schizophrenia Related to Duration of Attentional Blink? *Schizophrenia Research: Cognition*. (Accepted)
 62. Whitehorn D, Campbell ME, Cosgrove P, Abidi S, **Tibbo P**. (2016) A Mindfulness Based Support Group for Families in Early Psychosis: A pilot qualitative study. *Journal of Mental Health and Addiction Nursing*. (Accepted)
 63. Curran SR, Paya-Cano J, Witt SH, Lafuente A, Gasso P, MacIntyre G, Luoma LL, Bugbee DM, **Tibbo PG**, Purdon SE, Freeman B, Cohen-Woods S, Wong C, Price TS, Mill J, Santosh P, Ritschel M, Craig IW, Aitchison KJ. (2014) Sampling from challenging patient groups for genomics: which sample type? *Am J Med Genet Pt B (Neuropsychiatric Genets)*. (Submitted)

64. Ells E, Rudolph E, Sculthorpe-Petley L, Abriel S, Campbell D, **Tibbo P**, Fisher D. (2014) Alterations of mismatch negativity (MMN)-indexed central auditory processing elicited by a 'simple' pattern paradigm in early-phase psychosis patients. *Psychiatry Research: Neuroimaging*. (Submitted)
65. Purdon S, Macintyre G, Luoma L, Bowker A, Wild TC, **Tibbo P**. (2015) Social Anhedonia related to Catechol-O-Methyltransferase (COMT) in Healthy Young Adults. *Schizophrenia Research*. (Submitted)
66. Crocker C, Purdon S, Hanstock CC, Lakusta B, Seres P, **Tibbo P**. (2015) Enduring changes in brain metabolites and executive functioning in abstinent cocaine users. *Brain and Behaviour*. (Submitted)
67. Fisher D, Campbell D, Abriel S, Ella E, Rudolph E, **Tibbo P**. (2016) Alterations of Mismatch Negativity (MMN) and P300A Elicited by the 'Optimal' Multi-Feature Paradigm in Early-Phase Psychosis. *Clinical EEG & Neuroscience*. (Submitted)
68. Luoma LM, Macintyre G, **Tibbo P**, Wild TC, Coleman I, Purdon S. (2016) Association of NPAS3 exonic SNPs with working memory in healthy young adults. *Cognitive Neuropsychiatry*. (Submitted)
69. Lodhi RJ, Wang Y, Macintyre G, Bowker A, Crocker C, Ren H, Dimitrijevic A, Bugnee DA, Loverock A, Rossolatos D, Granger B, Sivapalan S, Newton VM, **Tibbo P**, Purdon SE, Aitchison KJ. (2016) Association between a functional variant in a gene encoding an enzyme metabolizing dopamine (catechol-O-methyltransferase) and post cannabis psychosis: a replication. *Biological Psychiatry*. (Submitted)
70. Cookey J, Crocker C, Bernier D, Newman A, Stewart S, **Tibbo P**. (2016) Microstructural changes in frontal white matter associated with cannabis use in early phase psychosis: A diffusion tensor imaging (DTI) study. (Submitted)
71. Crocker C, Tibbo P. (2017) 5 Things to Know About Cannabis and Mental Health. (Submitted)
72. Ursuliak Z, Crocker C, Hughes J, MacKenzie A, **Tibbo P**. (2016) Claymation Art Therapy as Adjunctive Treatment to Promote Recovery in Early Psychosis: A Pilot Study. (In preparation)
73. Crown M, **Tibbo P**, Crocker C. (2016) Family Outcomes from a Comparison of a Brief vs Longer Early Psychosis Family Education Program. (In preparation)
74. McAllindon D, Bowen C, Bernier D, **Tibbo P**. (2016) Method to Reduce 1H-MRS Acquisition Time by Correcting the Acquired Macromolecule Spectrum. (In preparation)

B) Abstracts:

1. Tibbo P., Silverstone P., McEwan A.J.B., Scott J., Joshua A., Golberg K. (1995). Striatal dopamine D2 receptor binding with ^{123}I -epidepride in schizophrenics and controls: an *in vivo* SPECT study. *Proceedings of the 45th Annual Meeting of the Canadian Psychiatric Association*, Victoria, BC.
2. McEwan A.J.B., Tibbo P., Silverstone P., Joshua A., Golberg K., Scott J. (1995). Epidepride. *Journal of Nuclear Medicine*, 36(5): 258P.
3. McEwan A.J.B., Tibbo P., Silverstone P., Joshua A., Golberg K., Scott J. (1995). Whole body distribution of ^{123}I -epidepride, a D2 receptor radiopharmaceutical. *European Journal of Nuclear Medicine*, 22(8): 930.
4. Tibbo P., Silverstone P., McEwan A.J.B., Scott J., Joshua A., Golberg K. (1995). Striatal dopamine D2 receptor binding with ^{123}I -epidepride, an *in vivo* SPECT study. *Proceedings of the 18th Meeting of the Canadian College of Psychopharmacology*, 45, Vancouver, BC.
5. Tibbo P., Silverstone P., McEwan A.J.B., Scott J., Joshua A., Golberg K. (1997). Striatal dopamine D2 receptor binding with ^{123}I -epidepride, an *in vivo* SPECT study. *Psychiatry Research: Neuroimaging*, 68: 180.
6. Tibbo P., Nopoulos P., Arndt S., Andreasen N. (1998). Shape and size of the corpus callosum in male schizophrenics. *Psychiatry Research: Neuroimaging*, 83: 52.
7. Tibbo P., Kroetsch M., Chue P. (1999). Investigation of obsessive-compulsive disorder in schizophrenia. *Schizophrenia Research*, 36, 1-3: 33.
8. Tibbo P., Hanstock C.C., Asghar S., Allen P.S. (1999) Proton magnetic resonance spectroscopy (^1H -MRS) of the cerebellar vermis in male schizophrenics. *Schizophrenia Research*, 36, 1-3: 248.
9. Prior T.I., Chue P.S., Tibbo P. (1999). Oral glucose challenge test abnormalities with atypical antipsychotic use. *Schizophrenia Research*, 36, 103: 357.
10. Prior T.I., Chue P.S., Tibbo P. (1999). Turner's syndrome in female schizophrenics. *Schizophrenia Research*, 36, 1-3: 94.
11. Tibbo P., Hanstock C.C., Thompson R.B., Valiakalayil A., Nopoulos P., Allen P.S. (1999). ^1H -MRS in adolescents at high-risk for schizophrenia. *Biological Psychiatry*, Suppl. 45(8S): 128S.
12. Li D., Chokka P., Mercer J., Scott J., McEwan A.J.B., Tibbo P. (1999). Dopamine and social phobia: a SPECT study using epidepride and beta-CIT. *Biological Psychiatry*, Suppl. 45(8S): 125S.
13. Li D., Chokka P., McEwan A., Logus W., Mantei S., Hanson J., Tibbo P. (2000). The relationship of striatal dopamine to social phobia and gender: a ^{123}I -epidepride SPECT study. *Proceedings of the 153rd American Psychiatric Association Annual Meeting*,

Research Colloquium for Junior Investigators, Chicago, Illinois, Travel Awardee Abstracts, 60.

14. Tibbo P., Chue P., Wright E., Metelitsa A., Joffe K. (2000). Longitudinal global assessment of functioning (GAF) following assertive community treatment (ACT). *Schizophrenia Research*, 41(1): 229.
15. Tibbo P., Nopoulos P., Allen P., Valiakalayil A. (2000). Home structure of adolescents at high-risk for schizophrenia. *Schizophrenia Research*, 41(1): 173.
16. Tibbo P., Valiakalayil A., Paulson L. (2000). Neuropsychological evaluations of high risk adolescents for schizophrenia. *Biological Psychiatry*, Suppl. 47(8S): 82S.
17. Li D., Chokka P., McEwan A.J.B., Logus W., Mantei S., Hanson J., Tibbo P. (2000). A SPECT study of gender and striatal dopamine. *Biological Psychiatry*, Suppl. 47, 8(5): 320S.
18. Tibbo P., Paulson L. (2000). Neuropsychological evaluations of high-risk adolescents for schizophrenia: the Edmonton high risk project. Presented at the *Canadian Psychiatric Association Annual Meeting*, Victoria, BC.
19. Tibbo P., Paulson L. (2000). Home structure of adolescents at high risk for schizophrenia: the Edmonton high risk project. Presented at the *Canadian Psychiatric Association Annual Meeting*, Victoria, BC.
20. Paulson L, Valiakalayil A., Tibbo P. (2001). New perspective on burden: adolescent children of schizophrenic parents. The Edmonton high risk study. *Schizophrenia Research*, Suppl. 14(102S): 142.
21. Tibbo P., Allen P., Hanstock C., Thompson R., Valiakalayil A., Paulson L. (2001). Proton magnetic resonance spectroscopy (¹H-MRS) and neuropsychological testing of adolescents at high risk for schizophrenia. *Schizophrenia Research*, Suppl. 14(1-2S) 196.
22. Tibbo P., Allen P., Hanstock C., Valiakalayil A., Jhangri G., Paulson L. (2001). Magnetic resonance spectroscopy (¹H-MRS) in adolescents at risk for schizophrenia. *The American Academy of Child and Adolescent Psychiatry Annual Meeting*, Hawaii.
23. Tibbo P., Allen P., Hanstock C., Valiakalayil A., Paulson L. (2002). Proton magnetic resonance spectroscopy (¹H-MRS) in adolescents at risk for schizophrenia. *Biological Psychiatry*, Suppl. 51(8S): 174S.
24. Tibbo P., Valiakalayil A., Paulson L. (2002). New perspective on burden: adolescent children of parents with schizophrenia. The Edmonton high risk project. *Acta Psychiatrica Scandinavica*, 106(413): 77S.
25. Tibbo P., Allen P., Hanstock C., Valiakalayil A., Paulson L. (2002). Proton magnetic resonance spectroscopy (¹H-MRS) in adolescents at risk for schizophrenia. The Edmonton high risk project. *Acta Psychiatrica Scandinavica*, 106(413): 77S.

26. Valiakalayil A., Tibbo P., Purdon S., Paulson L., Houser A. (2002). Neuropsychological evaluations of high risk adolescents for schizophrenia: a verbal relative to nonverbal deficit. The Edmonton high risk project. *Acta Psychiatrica Scandinavica*, 106(413): 78S.
27. Tibbo P., de Gara C., Blake T., Steinberg C., Stonehocker B. (2002). Perceptions of intimidation in the psychiatric educational environment in Edmonton, Alberta. *Proceedings of the Association for Academic Psychiatry Annual Meeting*, Toronto, ON.
28. Tibbo P., de Gara C., Blake T., Steinberg C., Stonehocker B. (2002). Perceptions of intimidation in the psychiatric educational environment in Edmonton, Alberta. *Proceedings of the 52nd Canadian Psychiatric Association Annual Meeting*, Banff, AB, 43S.
29. Tibbo P. (2002). Practice patterns of recent graduates from the psychiatry training program in Edmonton, Alberta. *Proceedings of the 52nd Canadian Psychiatric Association Annual Meeting*, Banff, AB, 44S.
30. Tibbo P., Allen P., Hanstock C., Valiakalayil A., Paulson L. (2003). Proton magnetic resonance spectroscopy (¹H-MRS) in adolescents at risk for schizophrenia. The Edmonton high risk project. *Schizophrenia Research*, Suppl. 60(1): 246.
31. Chan D., de Gara C.J., Tibbo P., Hanson J. (2003). The perceptions of intimidation and assertiveness in medical students and physicians. Presented at the *Association of Surgical Education (ASE)*, Vancouver, BC.
32. Purdon S.E., Tibbo P.G., Prior T.I. (2003). Progesterone elevations related to symptom severity but not anxiety in first break schizophrenia. *Proceedings of the 26th Canadian College of Neuropsychopharmacology (CCNP) Annual Meeting*, Montreal, Quebec, 75.
33. Hanstock C.C., Valiakalayil A., Paulson L., Allen P.S., Tibbo P. (2003). Numerical simulation to provide ¹H-MRS basis spectra for LCMoDel fitting: application to study adolescents at high risk for schizophrenia. *Scientific Section of the International Society for Magnetic Resonance in Medicine 11th Annual Meeting*, Toronto, ON.
34. Tibbo, P., Chan D., Hanson J., de Gara C. (2003). The relationships between intimidation and assertiveness in medical students at the University of Alberta. *Association for Academic Psychiatry (AAP) Annual Meeting*, Philadelphia, PA.
35. Shulman Y., Le Mellédo J-M., Tibbo P. (2004). Investigation of the CCK-B system in individuals comorbid with schizophrenia and anxiety disorders. Society of Biological Psychiatry 59th Annual Scientific Meeting, New York, NY. *Biological Psychiatry*, Suppl. 55(8S):21S.
36. Tibbo P., Valiakalayil A., Hanstock C., Purdon S. (2004). Longitudinal investigation of glutamate levels and cognitive impairment in adolescents at high risk for schizophrenia. Society of Biological Psychiatry 59th Annual Scientific Meeting, New York, NY. *Biological Psychiatry*, Suppl. 55(8S):218S.

37. Tibbo P., Purdon S., Valiakalayil A. (2004). Glutamate abnormalities in first episode patients and high risk candidates. 4th International Conference on Early Psychosis, Vancouver, BC. *Schizophrenia Research*, Suppl. 70(1):110.
38. Côté C., Valiakalayil A., Prior T., Purdon S., Tibbo P. (2004). Perceived caregiver burden contributes to participation in a family education program. 4th International Conference on Early Psychosis, Vancouver, BC. *Schizophrenia Research*, Suppl. 70(1):90.
39. Purdon S., Tibbo P., Prior T. (2004). Cognitive limitations in first episode schizophrenia associated with estrogen and progesterone. 4th International Conference on Early Psychosis, Vancouver, BC. *Schizophrenia Research*, Suppl. 70(1):107.
40. Purdon S., Tibbo P., Valiakalayil A. (2004). Glutamate modulation of perseveration in first episode schizophrenia. 4th International Conference on Early Psychosis, Vancouver, BC. *Schizophrenia Research*, Suppl. 70(1):105.
41. Shulman Y., Le Mellédo J-M., Bradley J., Tibbo P. (2004). Investigation of the CCK-B system in individuals with schizophrenia alone and in those with a comorbid anxiety disorder. 6th Annual Neuroscience Graduate Students' Association (NGSA) Research Day, Edmonton, AB.
42. Zedkova L., Woodward N.D., Shih E., Seres P., Purdon S.E., Tibbo P.G. (2005). Procedural learning in schizophrenia investigated with functional magnetic resonance imaging. *International Congress on Schizophrenia Research*, Savannah, Georgia, April 2-6, 2005. *Schizophrenia Bulletin*, 31(2): 441.
43. Valiakalayil A., Purdon S.E., Tibbo P.G. (2005). Glutamate modulation of perseveration in first episode Schizophrenia. *International Congress on Schizophrenia Research*, Savannah, Georgia, April 2-6, 2005. *Schizophrenia Bulletin*, 31(2): 446.
44. Tibbo P., Valiakalayil A., Seres P., Hanstock C. (2005). Comparison of glutamate levels in an older genetic high risk sample: useful predictor or genetic marker? *International Congress on Schizophrenia Research*, Savannah, Georgia, April 2-6, 2005. *Schizophrenia Bulletin*, 31(2): 446.
45. Shulman Y., Le Mellédo J-M., Tibbo P. (2005). The investigation of the CCK-B system in individuals comorbid with schizophrenia and anxiety disorders. *International Congress on Schizophrenia Research*, Savannah, Georgia, April 2-6, 2005. *Schizophrenia Bulletin*, 31(2): 293.
46. Purdon S.E., Tibbo P.G., Prior T.I. (2005). Clinical, psychosocial, and cognitive implications of estradiol and progesterone in first episode schizophrenia. *International Congress on Schizophrenia Research*, Savannah, Georgia, April 2-6, 2005. *Schizophrenia Bulletin*, 31(2): 292.
47. Tibbo P.G., McGrath B.M. (2005). Does progression through the medical curriculum influence students' perceptions of mental illness stigma and their willingness to seek help

for mental health problems: A naturalistic study. *Association for Academic Psychiatry Annual Meeting*, Chicago, IL, September 28 - October 1.

48. Alford T., Macintyre G., Tibbo P., Rouleau G., Cox D.W. (2005). Analysis of NPAS3: A candidate gene for schizophrenia. *Annual Summer Student Event*, Edmonton, AB, October 15.
49. Tibbo P., McGrath B.M. (2005). University students' perceptions of the stigma toward mental health consumers and their families: Does perception of stigma influence willingness to seek help for mental health problems? *55th Canadian Psychiatric Association Annual Conference*. Theme: Building Networks, Crafting Excellence. Vancouver, BC, November 3-6.
50. Tibbo, P. (2005). The Edmonton Early Psychosis Intervention Clinic (EEPIC) neuroimaging research. *Alberta Mental Health Board - Mental Health Research Showcase*. Theme: Advancing Mental Health Through Research, Innovation and Knowledge Translation. Banff, AB, November 28-30.
51. McGrath B.M., Tibbo P. (2005). Perceptions of stigma and willingness to seek mental healthcare among Canadian university students. *Alberta Mental Health Board - Mental Health Research Showcase*. Theme: Advancing Mental Health Through Research, Innovation and Knowledge Translation. Banff, AB, November 28-30.
52. Purdon S.E., Zedkova L., Woodward N., Tibbo P. (2005). Obstacles to rehabilitation in schizophrenia: a cerebral basis for skill acquisition deficits. *Alberta Mental Health Board - Mental Health Research Showcase*. Theme: Advancing Mental Health Through Research, Innovation and Knowledge Translation. Banff, AB, November 28-30.
53. Purdon S.E., Prior T.I., Shulman Y., Tibbo P.G. (2005). Cognitive limitations in first episode schizophrenia associated with estrogen and progesterone. *Alberta Mental Health Board - Mental Health Research Showcase*. Theme: Advancing Mental Health Through Research, Innovation and Knowledge Translation. Banff, AB, November 28-30.
54. Shulman, Y., Grant, S., Seres, P., Hanstock, C., Baker, G., Tibbo, P. (2006). Relationship between peripheral and central glutamate and glutamine levels in healthy individuals. *Biol Psychi 2006*, 59(Suppl 1-8): 1S-2645.
55. Kostov S, Tibbo P. (2006). A volumetric MRI study of the caudate nuclei in first-episode and chronic patients with schizophrenia. *Proceedings Faculty of Medicine and Dentistry 39th Summer Student Research Day* October 21, 2006.
56. Shulman, Y., Baker, G.B., Tibbo, P.G. (2006) Pregnenolone sulfate and dehydroepiandrosterone sulfate levels in individuals with first episode psychosis. *Proceedings of the Society for Neuroscience, Annual Convention*, October.
57. Valiakalayil A, Hanstock C, Seres P, Purdon S, Tibbo P. (2006). Relationship between in vivo glutamate levels and executive functioning in first episode schizophrenia. *Proceedings Biological Psychiatry*, Toronto, ON.

58. Valiakalayil A, Hanstock C, Seres P, Purdon S, Tibbo P. (2006). Proton MRS investigation of glutamate levels and executive functioning in first episode psychosis. *Proceedings 5th International Conference on Early Psychosis*, Birmingham UK 4-6 October 2006.
59. Macintyre G, Alford T, Xiang L, Rouleau G, Tibbo P, Cox D. (2006). Neuronal PAS gene, NPAS3, is a candidate for schizophrenia. *Proceedings World Congress on Psychiatric Genetics XIV*, Cagliari, Italy Oct 28 – Nov 01, 2006.
60. Valiakalayil A, Waldie, B., Bolt, C., Tibbo P., Purdon S. (2007). Personal and familial costs associated with the first episode of psychosis. *Proceedings International Congress on Schizophrenia Research, Colorado Springs, Schizophrenia Bulletin 33(2) 608*; March 2007.
61. Macintyre G, Alford T, Xiong L, Rouleau G, Tibbo P, Cox D. (2007). Association between the neuronal PAS gene, NPAS3, and schizophrenia. *Proceedings International Congress on Schizophrenia Research, Colorado Springs, Schizophrenia Bulletin 33(2) 300*; March 2007.
62. Purdon S, Shulman Y, Tibbo P. (2007). Substance induced psychosis and schizophrenia: Hormones for differential diagnosis. *Proceedings International Congress on Schizophrenia Research, Colorado Springs, Schizophrenia Bulletin 33(2) 209*; March 2007.
63. Shulman Y, Grant S, Baker G, Tibbo P. (2007). Investigation of amino acids involved in glutamatergic neurotransmission in first episode psychosis. *Proceedings International Congress on Schizophrenia Research, Colorado Springs, Schizophrenia Bulletin 33(2) 313*; March 2007.
64. Kostov, S., Valiakalayil, A., Seres, P., Tibbo, P. (2007). A volumetric magnetic resonance imaging study of caudate nuclei in first-episode and chronic patients with schizophrenia. *Proceedings International Congress on Schizophrenia Research, Colorado Springs, Schizophrenia Bulletin 33(2) 339*; March 2007.
65. Woodward, N., Tibbo, P., Purdon, S. (2007). An fMRI investigation of procedural learning in unaffected siblings of individuals with schizophrenia. *Proceedings International Congress on Schizophrenia Research, Colorado Springs, Schizophrenia Bulletin 33(2) 390*; March 2007.
66. Tibbo, P., Seres, P., Purdon, S., Concha, L. (2007). Diffusion tensor imaging of the fornix in unmedicated first episode schizophrenia. *Society of Biological Psychiatry, 62nd Annual Scientific Convention & Program, San Diego, CA, USA. May 17-19. Biological Psychiatry 61:(8S)253*
67. Tibbo, P., Valiakalayil A., Hanstock, C., Seres, P., Purdon, S. (2007). Longitudinal investigation of 1H-MRS metabolites in first episode psychosis. *Society of Biological Psychiatry, 62nd Annual Scientific Convention & Program, San Diego, CA, USA. May 17-19. Biological Psychiatry 61:(8S)259*

68. Tibbo, P., Valiakalayil A., Hanstock, C., Seres, P., Purdon, S. (2007). Relationship between Glutamate levels and age illness onset in schizophrenia versus substance induced psychosis. Society of Biological Psychiatry, 62nd Annual Scientific Convention & Program, San Diego, CA, USA. May 17-19. *Biological Psychiatry* 61 :(8S) 259.
69. Shulman, Y., Tibbo, P., Baker, G.B. (2007). Neuroactive steroids in first episode psychosis. Society of Biological Psychiatry, 62nd Annual Scientific Convention & Program, San Diego, CA, USA. May 17- *Biological Psychiatry* 61 :(8S) 161.
70. Shulman, Y., Baker, G.B., Tibbo, P. (2007). Neuroactive steroid plasma levels in patients with first episode psychosis. *Proc. Ann. Dept. of Psychiatry Research Day*, Edmonton Alberta, Canada, May 28.
71. Lichlyter, B., Purdon, S.E. & Tibbo, P.G. (2007, May). Reviewing the dangers of methamphetamine. An imaging-focused literature review. Poster session presented at the *Department of Psychiatry Research Day*, Edmonton, AB.
72. Goddard, K., Purdon, S., Tibbo, P. (2007). A comparison of self-report versus clinician-rated instruments in the assessment of obsessive compulsive symptoms in first episode psychosis. *Proceedings Flor Henry Annual Lecture*, Edmonton, 01 June 2007.
73. Lichlyter, B., Purdon, S.E. & Tibbo, P.G. (2007). Reviewing the dangers of methamphetamine. An imaging-focused literature review. Poster session presented at the *2007 Flor-Henry Annual Lecture*, Edmonton, AB. Canada 01 June.
74. Shulman, Y., Baker, G.B., Tibbo, P. (2007). Non-sulfated neuroactive steroid levels in first episode psychosis. *Flor Henry Annual Lecture*, Edmonton, Alberta, Canada 01 June.
75. Doktorchik, L., Purdon, S., Tibbo, P. (2007) Prolonged duration of untreated psychosis (DUP) predicts poor prognosis. *Mental Health Research Showcase*, Banff, Alberta, Canada. November 21-23.
76. Goddard, K., Purdon, S., Tibbo, P. (2007). The assessment of obsessive compulsive symptoms in first episode psychosis. *Mental Health Research Showcase*, Banff, Alberta, Canada. November 21-23.
77. Purdon, S., Valiakalayil, A., Hanstock, C., Seres, P., Tibbo, P. (2007). A biological (3T MRS glutamate) and psychological (CPT D') endophenotype for schizophrenia. *Mental Health Showcase*, Banff, Alberta, Canada. November 21-23.
78. Purdon, S., Doktorchik, L., Tibbo, P., Waldie, B., Goddard, K. (2007). Early weight gain predicts significant late weight gain after antipsychotic initiation in first episode psychosis. *Mental Health Research Showcase*, Banff, Alberta, Canada. November 21-23.
79. Lichlyter, B., Purdon, S., & Tibbo, P. (2007). Cognitive Assessment of Abstinent Methamphetamine Addicts: Investigation of Inhibitory Control. Abstract submitted to the *Alberta Mental Health Board Showcase*, Banff, AB, November 2007.

80. Lichlyter, B., Purdon, S., & Tibbo, P. (2007). Cognitive Assessment of Abstinent Methamphetamine Addicts: Investigation of Inhibitory Control. *Proceedings of American Academy of Addiction Psychiatry 18th Annual Meeting*, Coronado, California, November, 2007.
81. Goddard, K.M., Purdon, S.E., Tibbo, P. (2008). Low and stable CPT d'scores differentiate first episode schizophrenia from substance induced psychosis. *International Neuropsychological Society*, Waikola, Hawaii. February 6-9.
82. Goddard, K., Purdon, S., Tibbo, P. (2008). The assessment of obsessive compulsive symptoms in first episode psychosis: A comparison of self-report versus clinician-rated instruments. *International Neuropsychological Society*, Waikola, Hawaii. February 6-9.
83. McAllindon, D., Wilman, A.H., Purdon, S., Tibbo, P. (2008). Functional MRI of choice reaction time in chronic schizophrenia and first-degree relatives. *International Society of Magnetic Resonance in Medicine*. Toronto, Ontario, Canada. May 7-9, 2008
84. Harris, L., Tibbo, P. (2009). "Do patients follow-up with discharge advice after psychiatric assessment and discharge from emergency department?" *17th European Congress of Psychiatry*, Lisbon, January 24-28, 2009
85. Woodward, N., Waldie, B., Rogers, B., Tibbo, P., Seres, P., Purdon, S. (2009). The neural basis of response selections in schizophrenia: A potential endophenotype. Proceedings International Congress on Schizophrenia Research, San Diego, *Schizophrenia Bulletin* 35(1) 172; March 2009.
86. Purdon, S.E., Waldie, B., Woodward, N.D., Goddard, K., Seres, P., Tibbo, P.G. (2009). Cerebral Activation on fMRI during procedural learning in unmedicated first episode psychosis. Proceedings International Congress on Schizophrenia Research, San Diego, *Schizophrenia Bulletin* 35(1) 174; March 2009.
87. Lichlyter, B., Purdon, S., Tibbo, P. (2009). Early Stimulant Exposure is related to the severity of psychosis. Proceedings International Congress on Schizophrenia Research, San Diego, *Schizophrenia Bulletin* 35(1) 287; March 2009.
88. Good, K., Tibbo, P., Milliken, H.I., Whitehorn, D., Teehan, M., Alexiadis, M., Robertson, N., Ursuliak, Z., Abidi, S., Kopala, L.C. (2009). Impaired olfactory identification ability is associated with poorer functional outcome in patients with first episode psychosis. Proceedings International Congress on Schizophrenia Research, San Diego, *Schizophrenia Bulletin* 35(1) 332; March 2009.
89. Tibbo, P., Bernier, D., Seres, P., Hanstock, C., Purdon, S. (2009). Longitudinal investigation of 3T 1H-MRS and psychotic symptoms in unmedicated first episode psychosis. Proceedings International Congress on Schizophrenia Research, San Diego, *Schizophrenia Bulletin* 35(1) 154; March 2009.

90. Luoma, L.M., Macintyre, G., Purdon, S., Tibbo, P.G., Cox, D.W. (2009). Improving Outcomes in First Episode Psychosis: the Role of Genetic Variation of NPAS3. *Proceedings University of Alberta, Medical Genetics Research Day*, August 12, 2009.
91. Tibbo, P., Bernier, D., Seres, P., Hanstock, C., Nguyen-Burns, A., Purdon, S. (2009). Investigation of 3T 1H-MRS and psychotic symptoms in unmedicated first episode psychosis. *The 15th Biennial Winter Workshop in Psychoses*: 15-18 November 2009, Barcelona, Spain.
92. Lari, H., Colman, I., Bullard, M., Tibbo, P. (2009). Compliance & Outcome of Patients After Psychiatric Assessment and Discharge from Emergency Department. *The US Psychiatric and Mental Health Congress* – November 2009, Las Vegas.
93. Macintyre, G., Alford, T., Bugbee, D., Luoma, L., Xiong, L., Rouleau, G., Tibbo, P., Cox, D. NPAS3 variation: A positive association with schizophrenia. *3rd Annual Canadian Human Genetics Conference*. April 18-21, 2010. Saint-Saveur, Quebec.
94. Lichlyter, B., Purdon, S., Tibbo, P., Seres, P., Hanstock, C. (2009). A Proton magnetic Resonance Spectroscopy Investigation of Substance Induced Psychosis. *The Society of Biological Psychiatry 65th Annual Scientific Convention & Program*. May 20-22nd, 2010. New Orleans, Louisiana.
95. Luomo, L., Macintyre, G., Bugbee, D., Tibbo, P., Purdon, S., Cox, D. NPAS3: Assessing the function of a schizophrenia-associated transcription factor. *World Congress on Psychiatric Genetics*. October 3-7, 2010. Athens, Greece.
96. Lichlyter, B., Hanstock, C., Seres, P., Purdon, S., Bernier, D., Tibbo, P. Understanding stimulant-induced psychosis by co-registration of proton magnetic resonance spectroscopy and executive function. *Department of Psychiatry – 20th Annual Research Day*. October 14, 2010. Halifax, Nova Scotia.
97. Muir, A., Good, K., Tibbo, P. Cognitive remediation in first episode psychosis: A case study. *Department of Psychiatry – 20th Annual Research Day*. October 14, 2010. Halifax, Nova Scotia.
98. Tibbo, P., Sears, S., Milliken, H., Crown, M., Bernier, D. Help Seeking Pathways in First Episode Psychosis. *Department of Psychiatry – 20th Annual Research Day*. October 14, 2010. Halifax, Nova Scotia. *Eighth Atlantic Canada Psychosis Conference*. November 5, 2010. Halifax, Nova Scotia (Accepted). *7th International Conference on Early Psychosis*. Amsterdam, The Netherlands. *Early Intervention in Psychiatry* 4(S1) 178; November 2010.
99. Crown, M., Tibbo, P., Milliken, H., Whitehorn, D., Cosgrove, P. Working with Families: Issues in Program Development. *7th International Conference on Early Psychosis*. Amsterdam, The Netherlands. *Early Intervention in Psychiatry* 4(S1)168; November 2010
100. Lichlyter, B., Hanstock, C., Seres, P., Purdon, S., Bernier, D., Tibbo, P. Investigation of frontal 1H-MRS neurochemicals in young stimulant-abusing adults, with or without

persistent psychotic symptoms. *7th International Conference on Early Psychosis*. Amsterdam, The Netherlands. *Early Intervention in Psychiatry* 4(S1)161; November 2010.

101. Willinsky, C., Boydell, K., Baker, N., Tibbo, P., Nash, A., Norman, R., Windell, D., Singh, R., Erickson, D., Kutcher, S., Summerville, C. The subjective experience of cannabis use in early psychosis: A participatory action research approach. *7th International Conference on Early Psychosis*. Amsterdam, The Netherlands. *Early Intervention in Psychiatry* 4(S1)163; November 2010.
102. Tibbo, P., Sears, S., Milliken, H., Crown, M., Bernier, D., Dillen, K. Help Seeking Pathways in First Episode Psychosis. *International Congress On Schizophrenia Research* Colorado Springs, Colorado, USA. *Schizophrenia Bulletin* 37(S1)100; March 2011.
103. Good, K., Milliken, H., Leslie, R., Alexiadis, M., Robertson, N., Tibbo, P., Schellinck, H., Brown, R., Kopala, L. An Investigation of the Neural Correlates of Impaired Olfactory Identification Ability in Microsmic and Normosmic patients with First Episode Psychosis. *International Congress On Schizophrenia Research* Colorado Springs, Colorado, USA. *Schizophrenia Bulletin* 37(S1)137; March 2011.
104. Tibbo, P., Lichlyter, B., Hanstock, C., Seres, P., Purdon, S., Bernier, D. Neuroimaging and Cognitive Differentiation of Stimulant-Induced Psychosis from First Episode Psychosis. *15th World Congress of Psychiatry*. September 18-22, 2011. Buenos Aires, Argentina.
105. Luoma, L.M., Macintyre, G., LaFreniere, D., Beierbach, A., Berry, F., Purdon, S., Tibbo, P., Cox, D.W. Identification of Schizophrenia-Associated NPAS3 and COMT Exonic Variants in a Pre-Onset Aged Population. *12th International Congress of Human Genetics (ICHG)*. October 11-15, 2011. Montreal, Quebec.
106. Tibbo, P., Dillen, K., Sears, S., Bernier, D., Milliken, H., Crown, M. Pathways to Specialized Treatment for Psychosis. Psychiatry Research Day – Dalhousie University. October 28, 2011. Halifax, NS.
107. Tibbo, P., Bernier, D., Hanstock, C.C., Seres, P., Lichlyter, B., Purdon, S.E. 3-Tesla Proton Magnetic Spectroscopy in Unmedicated First Episode Psychosis: a Focus on Creatine. *The Society of Biological Psychiatry 67th Annual Scientific Convention*, May 2012, Philadelphia, PA.
108. Malla, A., Lepage, M., Tibbo, P. Negative symptoms in schizophrenia and related psychoses: Nature, Significance, Neurobiology and Treatment. *Canadian Psychiatric Association*. Symposium. September 27-29, 2012. Montreal, Quebec.
109. McLarnon, M., Pencer, A., Rostad, K., Abidi, S., Tibbo, P., Good, K. Investigating the nature of cognitive and psychosocial deficits in youth at ultra-high risk for psychosis. *8th International Conference on Early Psychosis*. San Francisco, California. *Early Intervention in Psychiatry* 6(S1)121; October 2012.
110. Purdon, S., Roper, L., Aitchison, K.J., Banasch, J., Boit, C., Cote, C., Goddard, K., Hibbard, K., Lafreniere, D., Oswald, R., Purser, St., Tibbo, P. Barriers to Care and

Duration of Untreated Psychosis in a First-Episode Psychosis Sample. *8th International Conference on Early Psychosis*. San Francisco, California. *Early Intervention in Psychiatry* 6(S1)112; October 2012.

111. Purser, S., Tibbo, P., Aitchison, K.J., Lafreniere, D., Robertson, R., Roper, L., Purdon, S. Utilization of Health Services and the Cost of Pathways to Care in First-Episode Psychosis in Alberta. *8th International Conference on Early Psychosis*. San Francisco, California. *Early Intervention in Psychiatry* 6(S1)104; October 2012.
112. Aydin, C., Tibbo, P., Ursuliak, Z. Psychosocial Interventions to Reduce Cannabis Use in the Early Psychosis Population. *8th International Conference on Early Psychosis*. San Francisco, California. *Early Intervention in Psychiatry* 6(S1)115; October 2012.
113. Whitehorn, D., Cosgrove, P., Campbell, M., Crown, M., Ursuliak, Z., Abidi, S., Tibbo, P. A Mindfulness-Based Support Group for Parents of Young People with Psychosis. *8th International Conference on Early Psychosis*. San Francisco, California. *Early Intervention in Psychiatry* 6(S1)88; October 2012.
114. Ayotte, B., Marcinkevics, D., Aitchison, K.J., Beierbach, A., Bolt, C., Colman, I., Cote, C., Lanfreniere, D., Tibbo, P., Wild, C., Wolfe, J., Purdon, S. Stressful Prenatal and Childhood Events and Adolescent Mental Health. *8th International Conference on Early Psychosis*. San Francisco, California. *Early Intervention in Psychiatry* 6(S1)125; October 2012.
115. Crown, M., Denaro, C., Tibbo, P., Good, K., Teehan, M., Whitehorn, D., Milliken, H. Changes in family caregiving appraisal, psychological distress, and knowledge of psychosis associated with psychoeducation offered in a first episode psychosis program (FEPP). *8th International Conference on Early Psychosis*. San Francisco, California. *Early Intervention in Psychiatry* 6(S1)93; October 2012.
116. Tibbo, P., Bernier, D., Hanstock, C.C., Seres, P., Lichlyter, B., Purdon, S.E. 3-Tesla Proton Magnetic Spectroscopy in Unmedicated First Episode Psychosis: a Focus on Creatine. *8th International Conference on Early Psychosis*. San Francisco, California. *Early Intervention in Psychiatry* 6(S1)46; October 2012.
117. Dimitrijevic, A., Yee, A., Luoma, L.M., Purser, S., Dillen, K., Tibbo, P.G., Purdon, S.E., Pazderka, H., Thomson, G., Bugbee, D.A., Veniamin, S., Kenney, S.M., Mason, M.L., Macintyre, G. The Applied Genomics Centre (TAGC). Applications: Multiplex approaches to SNP detection. *Med Gen Research Day 2012*. University of Alberta.
118. Luoma, L.M., Macintyre, G., Berry, F.B., LaFreniere, D., Purser, S., Beierbach, A., Tibbo, P., Cox, D.W., Purdon, S. Identifying Neuropsychological and Cognitive Endophenotypes of Schizophrenia-Associated Exonic Variants of NPAS3 and COMT. *62nd American Society of Human Genetics (ASHG)*. November 6-10, 2012. San Francisco, California.
119. McAllindon, D., Keefe, E.E., Tibbo, P., Eskes, G.A. Normalizing Working Memory for Serial Order in Schizophrenia (Control ID 1513521). *14th International Congress on*

Schizophrenia Research. Orlando, Florida. *Schizophrenia Bulletin* Vol 39 (S1) S241; May 2013.

120. Good, K., Barrett, S., Armstrong, M., Schlagentweit, H., Lewis, D., Tibbo, P., Milliken, H., Alexiadis, M., Robertson, N., Pencer, A., Morrison, J., Stewart, S. Tobacco cue-reactivity in smoking patients with early phase psychotic disorders: Preliminary data from a behavioral and fMRI study (Control ID 1521175). *14th International Congress on Schizophrenia Research*. Orlando, Florida. *Schizophrenia Bulletin* Vol 39 (S1) S241; May 2013.
121. Good, K., Lewis, D., Tibbo, P., Milliken, H., Alexiadis, M., Robertson, N., Whitehorn, D., Armstrong, M., Kopala, L. Understanding the Predictive Ability of Olfactory Dysfunction in First Episode Psychosis: Effects on Symptoms and Functional Outcome. *14th International Congress on Schizophrenia Research*. Orlando, Florida. *Schizophrenia Bulletin* Vol 39 (S1) S288; May 2013.
122. Tian, S.V., Lafreniere, D., Roper, L., Purser, S., Kluk, A., Tibbo, P., Purdon, S. Rapid Screening of Differential Cognitive Deficits in Schizophrenia and Substance Induced Psychosis. *74th Canadian Psychological Association Annual Meeting*. June 2013. Quebec City, Quebec.
123. Kluk, A., Tian, S.V., Lafreniere, D., Breierbach, A., Wild, C., Tibbo, P., Wolfe, J., Purdon, S. Stigma-related empathic attitudes and behavior associated with sub-clinical characteristics of psychosis in the observer. *74th Canadian Psychological Association Annual Meeting*. June 2013. Quebec City, Quebec.
124. Campbell, D., Abriel, S., Tibbo, P., Fisher, D. Auditory Change Detection in Early Psychosis: An Electrophysiological Investigation. *74th Canadian Psychological Association Annual Meeting*. June 2013. Quebec City, Quebec.
125. Varghese, A., Whitehorn, D., Lovas, J., Tibbo, P. Self-compassions, mindfulness and their relationship to depression and anxiety in individuals diagnosed with a psychotic disorder. *Department of Psychiatry 22nd Annual Research Day*, November 1, 2013. Halifax, NS.
126. Crocker, C., Bernier, D., Hanstock, C.C., Lakusta, B., Purdon, S.E., Seres, P., Tibbo, P. A view from the inside: Magnetic resonance spectroscopy on abstinent Cocaine addicts. *Department of Psychiatry 22nd Annual Research Day*, November 1, 2013. Halifax, NS.
127. Cookey, J., Bernier, D., McAllindon, D., Bartha, R., Hanstock, C.C., Newman, A., Stewart, S., Crocker, C., Good, K.P., Tibbo, P. Multimodal neuroimaging of white matter microstructure in early phase psychosis: the impact of early adolescent cannabis use. *Department of Psychiatry 22nd Annual Research Day*, November 1, 2013. Halifax, NS.
128. Butterfield, M., Tibbo, P., Bernier, D., Aitchison, K., Macintyre, G., Purdon, S., McAllindon, D., Moffatt, H. Neurological soft signs in psychosis: The potential impact of genetic variation on structural and functional abnormalities of the cerebellum. *Department of Psychiatry 22nd Annual Research Day*, November 1, 2013. Halifax, NS

129. Nolin, M., Abdel-Baki, A., Tibbo, P., Malla, A. Early Intervention for Psychosis in Canada: What is the State of Affairs? *World Congress on Brain, Behavior and Emotions*, April 7-9, 2014. Montreal, QC.
130. Tibbo, P., McAllindon, D., Bartha, R., Gallant, Michelle A., Bernier, D. 4 Tesla Proton Spectroscopy of Frontal White Matter in Early Phase Psychosis. *Society of Biological Psychiatry – 69th Annual Scientific Convention and Program*, May 8-10, 2014. New York, NY.
131. Tibbo, P., Malla, A., Abdel-Baki, A. Examination of Psychosis Early Intervention Programs in Canada: Towards national standards of program delivery and care. *XVI World Congress of Psychiatry*, September 14-18, 2014. Madrid, Spain.
132. Tibbo, P., Malla, A., Abdel-Baki, A., Nolin, M. Early Intervention for Psychosis in Canada: What is the State of Affairs? *Canadian Psychiatric Association (CPA) Annual Conference*, September 11-13, 2014. Toronto, Ontario. (Workshop).
133. Hastings, T., Tibbo, P., Williams, R. TMAS: A New Tool for the Monitoring of Antipsychotic Side Effects. *Canadian Psychiatric Association (CPA) Annual Conference*, September 11-13, 2014. Toronto, Ontario.
134. Malla, A., Tibbo, P., Jooper, R., Lal, S. Relapse Risk Assessment in Early Phase Psychosis: The Search for a Reliable and Valid Tool. *Canadian Psychiatric Association (CPA) Annual Conference*, September 11-13, 2014. Toronto, Ontario.
135. Nolin, M., Abdel-Baki, A., Tibbo, P., Malla, A. Early Intervention for Psychosis in Canada: What is the State of Affairs? *9th International Conference on Early Psychosis*, November 17-19, 2014. Tokyo, Japan.
136. Aitchison, K.J., Wang, Y., Heywood, B.A., Henriques, B.C., Rossolatos, D., Bugbee, D., Loverock, A., Bolt, C., Dimitrijevic, A., Macintyre, G., Tibbo, P., Purdon, S.E. Exploring the interplay between COMT, BDNF and AKT1 and cannabis consumption in psychotic disorders. *ACNP 53rd Annual Meeting*, December 7-11, 2014, Phoenix, Arizona.
137. Crocker, C., Seres, P., Purdon, S., Tibbo, P.G. The role of substance abuse in white matter integrity in First Episode Psychosis. *15th International Congress on Schizophrenia Research*, March 28-April 1, 2015. Colorado Springs, Colorado.
138. Tibbo, P.G., Bartha, R., McAllindon, D., Gallant, M., Bernier, D. Neurochemical Profile of Frontal White Matter in Early Phase Schizophrenia: A 1H-MRS Study at 4 Tesla. *15th International Congress on Schizophrenia Research*, March 28-April 1, 2015. Colorado Springs, Colorado.
139. Couture, M.E., Barrett, S., Tibbo, P., Stewart, S., Milliken, H., Pencer, A., Good, K. Exposure to tobacco-related cues does not enhance cravings in patients with psychotic disorders relative to control smokers. *15th International Congress on Schizophrenia Research*, March 28-April 1, 2015. Colorado Springs, Colorado.

140. Ursuliak, Z., Crocker, C., Hughes, J., Mackenzie, A., Tibbo, P. Claymation Art Therapy as Adjunctive Treatment to Promote Recovery in Early Psychosis: a Pilot Study. *15th International Congress on Schizophrenia Research*, March 28-April 1, 2015. Colorado Springs, Colorado.
141. Aitchison, K.J., Wang, Y., Heywood, B.A., Carvalho Henriques, B., Bugbee, D., Loverock, A., Bolt, C., Dimitrijevic, A., Macintyre, G., Tibbo, P., Purdon, S.E. Exploring the Interplay between COMT and Cannabis Consumption in Psychotic Disorders. *Society of Biological Psychiatry 70th Annual Scientific Meeting*, May 14-16, 2015. Toronto, Ontario.
142. Nolin M, Tibbo P, Malla A, Abdel-Baki A. Early Intervention for Psychosis in Quebec: What is the State of Affairs?: A closer look at practices and challenges facing both academic and non academic programs. Université de Montréal's Journée de la Recherche, September 2015.
143. Shalini L, Marandola G, Theriault J, Tibbo P, Manchanda R, Williams R, Joober R, Banks N, Malla A. How do family members of young people receiving services for a first-episode psychosis recognize relapse and its early warning signs? *Canadian Psychiatric Association (CPA) 65th Annual Conference*, October 1-3, 2015. Vancouver, British Columbia.
144. Tibbo P, Malla A, Lal S, Lutgens D, Cheng C, Shah J. Challenges Facing Early Psychosis Services. *Canadian Psychiatric Association (CPA) 65th Annual Conference*, October 1-3, 2015. Vancouver, British Columbia.
145. Tibbo P. Schizophrenia and Related Psychosis Clinical Care Pathway Redesign. *Canadian Psychiatric Association (CPA) 65th Annual Conference*, October 1-3, 2015. Vancouver, British Columbia.
146. Lepage M, Tibbo P, Shah J, Chakravatry M, Palaniyappan L. The psychosis continuum: Neuroimaging explorations of at-risk and first episode populations. *Joint CCNP/CDRIN Meeting*, June 14-17, 2016. Halifax, Nova Scotia. (Accepted)
147. Tibbo P, Borsato A, Hardy K, Banks N. ARC Self Assessment Program (Poster). *Canadian Psychiatric Association (CPA) Annual Conference*, September 22-24, 2016. Toronto, Ontario. (Accepted)
148. Tibbo P, Malla A, Hastings T. New Clinical Tools for Intervention in Early Psychosis (Workshop). *Canadian Psychiatric Association (CPA) Annual Conference*, September 22-24, 2016. Toronto, Ontario. (Accepted)
149. Fisher D, Tibbo P. Mismatch Negativity (MMN) Elicited by Simple Deviance and Pattern Deviance in Early Psychosis. *Society for Psychophysiological Research (SPR) Annual Meeting*, September 21-25, 2016. Minneapolis, Minnesota. (Accepted)
150. Aitchison K, Lodi R, Wang Y, Rossolatos D, Whitford R, Macintyre G, Crocker C, Flanagan RJ, Rietschel M, Mors O, Henigsberg N, Hauser J, Astrid Z, Maier W, Dernovsek M, Souery D, Cattaneo A, Uher R, Craig IWC, McGuffin P, Henriques B, Sivapalan S,

- Tibbo P, Purdon SE. Effects of Gender on Moderating Gene-environment Interactions in Depression and Psychosis. *Society of Biological Psychiatry Meeting 2016*. (Submitted)
151. Lodhi RJ, Wang Y, MacIntyre G, Crocker C, Carvalho Henriques B, Sivapalan S, Rossolatos D, Whitford R, Tibbo P, Purdon SE, Aitchison KJ. In young Canadians, COMT and BDNF variants significantly affect age of onset of psychosis after cannabis use. *Canadian College of Neuropsychopharmacology (CCNP) Annual Meeting*, June 14-17, 2016. Halifax, Nova Scotia. (Submitted)
 152. Tibbo P, Ursuliak Z, Abidi S, Crown M, Crocker C, Hughes J. Improving the transition from early intervention services to community care. *International Early Psychosis Association (IEPA) Bi-annual Meeting*, October 20-22, 2016. Milan, Italy. *Early Intervention in Psychiatry* 10(C54): 213 October 2016.
 153. Roy MA, Malla A, Joober R, Demers MF, Abdel Baki A, Raedler T, Banks N, Tibbo P, Agid O, Williams R. Clozapine use in Early Intervention programs across Canada. *International Early Psychosis Association (IEPA) Bi-Annual Meeting*, October 20-22, 2016. Milan, Italy. *Early Intervention in Psychiatry* 10(A104): 148 October 2016.
 154. Lal S, Czesak A, Marandola G, Tibbo P, Manchanda R, Williams R, Joober R, Banks N, Malla A. Factors Related to Relapse from the Perspectives of Young Adults Receiving Services for First-Episode Psychosis. *International Early Psychosis Association (IEPA) Bi-Annual Meeting*, October 20-22, 2016. Milan, Italy. *Early Intervention in Psychiatry* 10(A87): 143 October 2016.
 155. Tibbo P, Abidi S, Methot D, Burke L, Whitehorn D. Key Findings in Early Psychosis: A knowledge sharing initiative. *International Early Psychosis Association (IEPA) Bi-Annual Meeting*, October 20-22, 2016. Milan, Italy. *Early Intervention in Psychiatry* 10(A99): 147 October 2016.
 156. Tibbo P for the Canadian Consortium on Early Intervention in Psychosis. The CCEIP Decision-Making Tool. *International Early Psychosis Association (IEPA) Bi-Annual Meeting*, October 20-22, 2016. Milan, Italy. *Early Intervention in Psychiatry* 10(A113): 151 October 2016.
 157. Tibbo P for the Canadian Consortium on Early Intervention in Psychosis. The CCEIP Relapse Risk Assessment in Early Phase Psychosis Questionnaire. *International Early Psychosis Association (IEPA) Bi-Annual Meeting*, October 20-22, 2016. Milan, Italy. *Early Intervention in Psychiatry* 10(A114): 151 October 2016.
 158. Tibbo P, Achim A, Malla A, Banks N, Roy MA. Preliminary exploration of the current use of long-acting injectable antipsychotics in Canadian early intervention services for psychosis. *International Early Psychosis Association (IEPA) Bi-Annual Meeting*, October 20-22, 2016. Milan, Italy. *Early Intervention in Psychiatry* 10(B80): 179 October 2016.
 159. Nolin M, Abdel-Baki A, Tibbo P, Banks N, Malla A. Early Intervention for Psychosis in Quebec (Canada): Successes and Challenges for Both Academic and Non-Academic

Programs. *International Early Psychosis Association (IEPA) Bi-Annual Meeting*, October 20-22, 2016. Milan, Italy. *Early Intervention in Psychiatry* 10(C45): 210 October 2016.

160. Aitchison KJ, Lodhi R, Crocker C, Macintyre G, Tibbo P, Purdon SE. Cannabis: is this really harmless? Plenary Keynote Speech, *7th World Gene Convention 2016*, November 3, 2016. Shanghai, China. (Accepted)
161. Crocker C, McAllindon D, Bernier D, Jakeman D, Tibbo PG. Differences in Brain Metabolites Between Males and Females with First-Episode Psychosis. Dalhousie Department of Psychiatry 26th Annual Research Day, October 14, 2016. Halifax, Nova Scotia. (Poster)
162. Holmans M, Tibbo PG, Crocker CE. A preliminary study of cannabis use impact on females with early psychosis. Dalhousie Department of Psychiatry 26th Annual Research Day, October 14, 2016. Halifax, Nova Scotia. (Poster)
163. Sapieha M, Tibbo PG. Gender differences in engagement through the early psychosis program based on initial referral source. Dalhousie Department of Psychiatry 26th Annual Research Day, October 14, 2016. Halifax, Nova Scotia. (Poster)
164. Higgins K, Pencer A, Tibbo P, Crocker C. Impact of an early psychosis program on cognitive functioning: An examination of time and sex differences in the first six months of treatment. Dalhousie Department of Psychiatry 26th Annual Research Day, October 14, 2016. Halifax, Nova Scotia. (Poster)
165. Tibbo P. Service Delivery Research in Early Intervention for Psychosis. Dalhousie Department of Psychiatry 26th Annual Research Day, October 14, 2016. Halifax, Nova Scotia. (Oral presentation)

C) Book Chapters:

McAllindon, D., Tibbo, P. “Directions in Research into Response Selection Slowing in Schizophrenia” in *Neuropsychiatric Disorders*, published by InTech (open access) edited by Dr. T.H.J. Burne of University of Queensland – 2011.

Crocker, C., Cooney, J., Tibbo, P. “Neuroimaging Findings in Adolescent Cannabis use and Early Phase Psychosis” in *Handbook of Cannabis and Related Pathologies: Biology, Diagnosis, Treatment and Pharmacology*. Victor R. Preedy (Editor). Academic Press. (Publisher) – *Handbook of Cannabis and Related Pathologies*. Chapter 36; 345-356.

Crocker, C., Tibbo, P. “White matter, schizophrenia and cannabis” in *The Neuropathology of Drug Addictions and Substance Misuse*. Victor R. Preedy (Editor). Elsevier Inc. (Publisher) – 2015.

Book Chapters in preparation:

D) Invited Presentations/Workshops:

1. Treatment resistant schizophrenia. Moderator of workshop at Update on the Management of Psychosis, Edmonton, 1998.
2. Overview of schizophrenia: from diagnosis to pharmacotherapy. University of Alberta Pharmacy Alumni Association Annual Meeting, Edmonton, 1998.
3. New Research in Schizophrenia. National Mentor/Teacher for National Program, Toronto, 1998.
4. Effects of major mental illness on parenting assessment and intervention. Moderator for workshop at Update on the Management of Psychosis, Edmonton, 1999.
5. Cerebral aspects to the onset, course and treatment of schizophrenia. Moderator of workshop at Update on the Management of Psychosis, Edmonton, 1999.
6. Schizophrenia - youth's disabler. NMR Research Group, University of Alberta, Edmonton, 1999.
7. The overlap of OCD and schizophrenia considerations in cause and treatment. Space Science Centre, Edmonton, 1999.
8. Edmonton high risk project. Schizophrenia Society of Alberta Annual Meeting, Edmonton, 1999.
9. Investigation of adolescents at high risk for schizophrenia. 7th Annual Schizophrenia Conference, Edmonton, 1999.
10. Experience of children living with parents with schizophrenia. 7th Annual Schizophrenia Conference, Edmonton, 1999.
11. Raising the standards of wellness for patients with schizophrenia and psychotic disorders. Workshop at 4th Annual Western Canada Schizophrenia Conference, Edmonton, 1999.
12. Investigation of adolescents at high risk for schizophrenia. Department of Psychiatry Grand Rounds, University of Alberta Hospitals, Edmonton, 1999.
13. Adolescents at risk for schizophrenia. Update on the Management of Psychosis, Edmonton, 2000.
14. Update on the Edmonton adolescent high risk project. 8th Annual Schizophrenia Conference, Edmonton, 2000.
15. The Edmonton adolescent high risk project. Brain MR Research Group seminar, Edmonton, 2001.

16. Assessment of adolescents at risk for schizophrenia: The Edmonton high risk project. Presentation in Grande Prairie, 2001.
17. Edmonton high risk project. Department of Psychiatry Grand Rounds, University of Calgary, Calgary, 2001.
18. Edmonton high risk project. Department of Psychiatry Grand Rounds, University of Alberta Hospitals, Edmonton, 2001.
19. The adolescents at risk project: the experience of children living with a parent or sibling with mental illness. BRIDGES 5th Annual General Meeting, Hinton, AB, 2001.
20. Edmonton Early Psychosis Intervention Clinic (EEPIC) proposal. Presented at Edmonton Chapter of American Psychiatric Association Fall Meeting, Edmonton, 2001.
21. Edmonton high risk project. Department of Psychiatry Grand Rounds, Grey Nuns Hospital, Edmonton, 2001.
22. Bebensee Schizophrenia Research Unit (BSRU). Presented at Unsung Heroes (advocacy group), Edmonton, 2002.
23. CanMeds Project and Residency Training Workshop, Edmonton, 2002.
24. First break psychosis and the Edmonton Early Psychosis Intervention Clinic (EEPIC). Department of Psychiatry Grand Rounds, University of Alberta Hospitals, Edmonton, 2002.
25. Pharmacologic management of schizophrenia and related disorders. Psychologists' Association of Alberta Annual Meeting, Edmonton, 2002.
26. Bebensee Schizophrenia Research Unit (BSRU). 2002 National Leadership Conference, Edmonton.
27. Schizophrenia research at the University of Alberta. Summer student research presentations, University of Alberta, Edmonton, 2002.
28. Introduction to psychosis. Edmonton Early Psychosis Intervention Clinic (EEPIC) Family Workshop, Edmonton, 2002.
29. Edmonton Early Psychosis Intervention Clinic (EEPIC). Department of Psychiatry Grand Rounds, Royal Alexandra Hospital, Edmonton, 2002.
30. Adolescents at high risk for schizophrenia: an update on the Edmonton neuroimaging and cognition research project. Department of Psychiatry Grand Rounds, University of Calgary, Calgary, 2003.
31. Introduction to psychosis. Edmonton Early Psychosis Intervention Clinic (EEPIC) Family Workshop, Edmonton, 2003.

32. Transition to Practice Workshop for PGY-V Psychiatry Residents, UAH, Edmonton, 2003.
33. Psychiatry. Medical Students Careers Week, University of Alberta, Edmonton, 2004.
34. Psychiatry as a career. Undergraduate Psychiatry Club, University of Alberta, Edmonton, 2004.
35. Balancing work and life. Psychiatry Residents' Well-Being Retreat, Edmonton, 2004.
36. The investigation of glutamate in at-risk populations for schizophrenia. Neuroscience Seminar Series, Edmonton, 2004.
37. Edmonton Early Psychosis Intervention Clinic (EEPIC). A Channel News - Health Watch, Edmonton, 2004.
38. Standardization of Preceptors for Long-Case Oral Exams. Royal College Exam Format Workshops Grey Nuns Hospital and University of Alberta Hospitals, Edmonton, 2004.
39. Introduction to Psychosis. Edmonton Early Psychosis Intervention Clinic (EEPIC) Family Workshop, Edmonton, 2004.
40. Case Panel - Clinical Dilemmas in Treatment Resistant Psychosis. 8th Annual Update on the Management of Psychosis, Edmonton, 2005.
41. Schizophrenia Research in Edmonton: The Bebensee Schizophrenia Research Unit. Society of Schizophrenia of Alberta Provincial Board Meeting, Calgary, June 16, 2005.
42. Ask the Doctor - A Family Session. Panel Session Workshop. National Mental Health Conference 2005, Edmonton, September 22, 2005
43. The Edmonton Early Psychosis Intervention Clinic (EEPIC) Neuroimaging Research. Mental Health Research Showcase, Banff, Alberta, November 28-30, 2005.
44. Introduction to psychosis. Edmonton Early Psychosis Intervention Clinic (EEPIC) Family Workshop, Edmonton, 2005.
45. National Schizophrenia Bureau Meeting, Quebec City, 24-26 February, 2006.
46. Key Note Speaker Sebastian Littman Research Day, University of Calgary: "Neuroimaging in Schizophrenia: from resident elective to career choice", 03 March 2006.
47. National Schizophrenia Bureau Meeting, Calgary, 24 February 2007.
48. Grand Rounds Alberta Hospital Edmonton: "First Episode Psychosis: Innovations and Repetitions", 22 June 2007.

49. British Columbia Psychiatric Association Annual Meeting – Advancement in the Treatment of Addiction: “Identifying and Managing Risk Factors across Psychiatric Disorders”, November 3, 2007.
50. Nova Scotia Early Psychosis Program Network (Workshop/Annual meeting). “Schizophrenia Research today”, Halifax, Nova Scotia, November 21, 2008
51. University Rounds, Dalhousie University (QEII), “Pathways to Care in Psychosis”, Halifax, Nova Scotia, November 26th, 2008.
52. Nova Scotia Hospital Grand Rounds, “Pathways to Care in Psychosis”, Halifax, Nova Scotia, December 12th, 2008.
53. Department of Anatomy, Dalhousie University Grand Rounds, Halifax, NS, May 8, 2009
54. Dalhousie University, Department of Psychology Colloquium, Adjunct talk. Defining an endophenotype for psychosis: A collaborative approach, October 23, 2009.
55. 2010/2011 CIHR Café Scientifique Program, “The vicious cycle: The link between substance misuse and mental health disorders”, Halifax, Nova Scotia, October 13, 2010.
56. East Hants, Nova Scotia, presentation - The Use of Rating Scales in Clinical Practice for First Episode Psychosis (FEP) – October 21, 2010.
57. Eighth Atlantic Canada Psychosis Conference – “Recovery: From Theory to Practice”, Halifax, Nova Scotia, November 5, 2010.
58. Integration Service Evaluation Working Group, Dartmouth, NS, April 5, 2011.
59. Invited speaker - LAI talks to MD’s, RN’s, St. John’s, Newfoundland, April 7/8, 2011.
60. First Episode Psychosis (Presentation), Saskatchewan, April 15, 2011.
61. Invited speaker - LAI talks to MD’s (CBDHA), Sydney, Cape Breton, May 11, 2011.
62. 15th World Congress of Psychiatry, Symposium – Early Diagnosis and Prediction of Outcome in Psychotic Disorders at First Episode: Some New Evidence – Early Case Identification and Stability of Diagnosis in First Episode Psychosis, Buenos Aires, Argentina, September 18-22, 2011.
63. Inter-professional Education Series – Reported Stigma and Discrimination by People with a Diagnosis of Schizophrenia, Dartmouth, NS, September 27, 2011.
64. This Week in Psychiatry – NSH Inter-Professional Education Series – “The Experience of and working with Stigma in First Episode Psychosis”, Dartmouth, NS, September 27, 2011.

65. Presentation - LAI use in Canada – Workshop, Wolfville, NS, April 18, 2012.
66. Lunch & Learn (Janssen-Ortho) - A Debate: Are Long-Acting Antipsychotic Medications Being Under-Utilized? Antigonish, NS, June 27, 2012.
67. Talk – General Practitioners (HRM) – First-Episode Psychosis: Early Intervention and Treatment, Halifax, NS, October 27, 2012.
68. Canadian Psychiatric Association. Symposium - Negative symptoms in schizophrenia and related psychoses: Nature, Significance, Neurobiology and Treatment. September 27-29, 2012. Montreal, Quebec.
69. Presentation – LAI use in Canada – Workshop, Bridgewater, NS, January 9, 2013.
70. Presentation – Sunovion – “The Evolving Landscape of Pharmacotherapy in Schizophrenia”, Halifax, NS, February 21, 2013.
71. Presentation – The HRM Chapter (Schizophrenia Society of NS) – Family Education & Support, Halifax, NS, April 8, 2013.
72. Presentation – “Psychosis: The Nova Scotia Early Psychosis Program and Current Research”, Pictou, NS, May 13, 2013.
73. Panel Discussion (Janssen) - “LAI use in Canada”, Toronto, Ontario, May 14, 2013.
74. Presentation LAIs: “Clinical Recommendations” (CPA Accredited Program) – Sydney, NS – May 31, 2013, (Cobequid) Lower Sackville, NS – June 7, 2013, Fredericton/Saint John, NB – June 12, 2013, St. John’s, NFLD – September 12, 2013.
75. Presentation Canadian College of Health Leaders (CCHL) HPRS – “Improving Outcomes: LAI use in Canada”, Vancouver, BC, September 18, 2013.
76. ECNP – “Future treatment options for negative symptoms: are we hitting the target”, Barcelona, October 4, 2013.
77. Grand Rounds – “Re-examining negative symptoms and potential future treatment options”, Halifax, NS, November 13, 2013.
78. Presentation – SSNS 25th Annual Conference – “The Nova Scotia Early Psychosis Program and Network, Halifax, NS, November 15, 2013.
79. Presentation – The Management of Schizophrenia and the Role of LAIs – Otsuka/Lundbeck, Toronto, Ontario, January 29, 2014.
80. Presentation – LAIs: “Clinical Recommendations” – (CPA Accredited Program), Lethbridge, Alberta, January 30-31, 2014.
81. Presentation - Canadian Centre on Substance Abuse – “The Impact of Cannabis on the Developing Brain: A focus on Psychosis”, Toronto, Ontario, February 25, 2014.

82. Round Table Discussion – “Health Risks of Marijuana use for Youth” – Federal Minister of Health – Honorable Rona Ambrose, Ottawa, Ontario, April 30, 2014.
83. Presentation – Knowledge Sharing Conference – “Key Findings in Early Psychosis: A Knowledge Sharing Initiative” – Annapolis Valley, NS – May 29, 2014, Sydney, NS – June 2, 2014, Halifax, NS – June 13, 2014.
84. Presentation – Atlantic Provinces Psychiatric Association (APPA) – “The use of Long Acting Injectable Antipsychotics (LAIs) in the Canadian setting”, Western Shore, NS, June 6, 2014.
85. Presentation – Dalhousie University Academic Grand Rounds – “Cannabis and Psychosis: What’s the buzz?”, Halifax, NS, January 28, 2015.
86. Presentation – University of Calgary Psychosis Day – “Examination of Early Psychosis Intervention Programs in Canada: Towards National Standards of Program Delivery of Care”, Calgary, AB, Feb 5, 2015.
87. Presentation – Alberta Psychiatric Association (APA) Annual Meeting – “Optimizing Outcomes in Early Phase Psychosis”, Banff, AB, March 21, 2015.
88. Presentation – Knowledge Sharing Conference – “Key Findings in Early Psychosis: A Knowledge Sharing Initiative” – Amherst, NS – October 30, 2015, Halifax, NS – November 6, 2015.
89. Live Panel Discussion – Canadian Centre on Substance Abuse (CCSA) Youth and Cannabis Panel – “Myth Busting: What the research evidence actually says about the effects of youth cannabis use on the developing brain”, Halifax, NS, January 15, 2016.

E) Community/Media Presentations (selected):

1. Psychiatry: mind matters. Presentation at Strathcona Composite High School, Edmonton, 1998.
2. Edmonton Early Psychosis Intervention Clinic (EEPIC). Mental Health Awareness Week, Edmonton, 2004.
3. Edmonton Early Psychosis Intervention Clinic (EEPIC). A Channel News - Health Watch, Edmonton, 2004.
4. 3-T Proton MRS Investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. (2004) In *Psychiatric News*, 39(12): 30.
5. Doc-Talk. Eastlink, Halifax, 2009.
6. Public Lecture – Mind Matters. Mental Health Awareness Week, Halifax/Dartmouth, 2009.

7. Road to Recovery Walkathon – NS Schizophrenia Society – Key Note Speaker. Halifax, 2009.
8. Invited guest speaker – Mental Health Foundation of Nova Scotia – AGM. Halifax, June 25, 2009.
9. Public Lecture - Canadian Psychiatry Research Foundation (CPRF), Halifax, NS, November 7, 2009.
10. Halifax Chapter - Schizophrenia Society of Nova Scotia, Halifax, NS, February 8, 2010.
11. This Week in Psychiatry - NSH Inter-Professional Education Series – “The experience of, and working with, Stigma in First Episode Psychosis”, Dartmouth, NS, September 27, 2011.
12. Presentation – Citadel High School – “Psychosis – early warning signs”, Halifax, NS, June 11, 2012.
13. Interview – Toronto Star – Children of Parents with Mental Illness, Halifax, NS, August 17, 2012.
14. Public Lecture – RISE Lecture Series – “The Changing Meaning of Recovery from Mental Disorder”, Halifax, NS, November 19, 2012.
15. 86th Annual Dalhousie Refresher Course – World Trade & Convention Centre, Halifax, NS, November 29th – December 1st, 2012.
16. Training - Addiction Prevention Treatment Services (APTS), Halifax, NS, December 7, 2012.
17. Cannabis and Psychosis – “The Dahlia Show” – CJOB (Radio), Winnipeg, Manitoba, September 9, 2013.
18. Cannabis and Psychosis – CTV Morning Live, Halifax, NS, September 11, 2013.
19. Cannabis and Psychosis – Maritime Morning Weekend Edition with Scot Simpson, News 95.7 (Radio), Halifax, NS, September 15, 2013.
20. Study Probes Effect of Cannabis on Brain - Researchers seek reasons drug can prompt psychosis in youth – The Chronicle Herald (Newspaper), Halifax, NS, January 7, 2014.
21. Providing optimism for psychosis through early intervention services – The National Post. Toronto, Ontario, March 22, 2014.
22. Mental Health Minute – CTV News at 5 – “Impact Marijuana has on Mental Health”. Halifax, NS, July 15, 2014.
23. Cannabis and Psychosis – World Report (National Health and Medical) – CBC Radio – Halifax, NS, September 11, 2014.

24. “Mental Health Group Mulls Age Restriction for Marijuana Use” – The Lobby Monitor – October 17, 2016.
25. “Cannabis age” – News Talk 770 Radio. Calgary, AB, February 3, 2017.